

Contents

Glossary	xii
Acronyms	xiv
1 Introduction and Literature Review	1
1.1 Cancer Research in the Post-Genomic Era	1
1.1.1 Cancer as a Global Health Concern	1
1.1.1.1 The Genetics and Molecular Biology of Cancers	3
1.1.2 The Human Genome Revolution	6
1.1.2.1 The First Human Genome Sequence	6
1.1.2.2 Impact of Genomics	7
1.1.3 Technologies to Enable Genetics Research	7
1.1.3.1 DNA Sequencing and Genotyping Technologies	7
1.1.3.2 Microarrays and Quantitative Technologies	8
1.1.3.3 Massively Parallel “Next Generation” Sequencing . . .	9
1.1.3.3.1 Molecular Profiling with Genomics Technology .	10
1.1.3.3.2 Sequencing Technologies	11
1.1.3.4 Bioinformatics as Interdisciplinary Genomic Analysis .	12
1.1.4 Follow-up Large-Scale Genomics Projects	12
1.1.5 Cancer Genomes	13
1.1.5.1 The Cancer Genome Atlas Project	14
1.1.5.1.1 Findings from Cancer Genomes	15
1.1.5.1.2 Genomic Comparisons Across Cancer Tissues .	16
1.1.5.1.3 Cancer Genomic Data Resources	17
1.1.6 Genomic Cancer Medicine	18
1.1.6.1 Cancer Genes and Driver Mutations	18
1.1.6.2 Personalised or Precision Cancer Medicine	19
1.1.6.2.1 Molecular Diagnostics and Pan-Cancer Medicine	20
1.1.6.3 Targeted Therapeutics and Pharmacogenomics	20
1.1.6.3.1 Targeting Oncogenic Driver Mutations	21
1.1.6.4 Systems and Network Biology	21
1.1.6.4.1 Network Medicine, and Polypharmacology . . .	24
1.2 A Synthetic Lethal Approach to Cancer Medicine	25
1.2.1 Synthetic Lethal Genetic Interactions	25
1.2.2 Synthetic Lethal Concepts in Genetics	26
1.2.3 Studies of Synthetic Lethality	27

1.2.3.1	Synthetic Lethal Pathways and Networks	27
1.2.3.1.1	Evolution of Synthetic Lethality	28
1.2.4	Synthetic Lethal Concepts in Cancer	29
1.2.5	Clinical Impact of Synthetic Lethality in Cancer	30
1.2.6	High-throughput Screening for Synthetic Lethality	32
1.2.6.1	Synthetic Lethal Screens	34
1.2.7	Computational Prediction of Synthetic Lethality	37
1.2.7.1	Bioinformatics Approaches to Genetic Interactions . .	37
1.2.7.2	Comparative Genomics	38
1.2.7.3	Analysis and Modelling of Protein Data	41
1.2.7.4	Differential Gene Expression	42
1.2.7.5	Data Mining and Machine Learning	43
1.2.7.6	Bimodality	46
1.2.7.7	Rationale for Further Development	47
1.3	E-cadherin as a Synthetic Lethal Target	47
1.3.1	The <i>CDH1</i> gene and it's Biological Functions	48
1.3.1.1	Cytoskeleton	48
1.3.1.2	Extracellular and Tumour Micro-Environment	48
1.3.1.3	Cell-Cell Adhesion and Signalling	49
1.3.2	<i>CDH1</i> as a Tumour (and Invasion) Suppressor	49
1.3.2.1	Breast Cancers and Invasion	49
1.3.3	Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer .	50
1.3.4	Models of <i>CDH1</i> loss in cell lines	51
1.4	Summary and Research Direction of Thesis	51
1.4.1	Thesis Aims	53
2	Methods and Resources	55
2.1	Bioinformatics Resources for Genomics Research	55
2.1.1	Public Data and Software Packages	55
2.1.1.1	Cancer Genome Atlas Data	56
2.1.1.2	Reactome and Annotation Data	57
2.2	Data Handling	57
2.2.1	Normalisation	57
2.2.2	Sample Triage	58
2.2.3	Metagenes and the Singular Value Decomposition	60
2.2.3.1	Candidate Triage and Integration with Screen Data . .	60
2.3	Techniques	61
2.3.1	Statistical Procedures and Tests	61
2.3.2	Gene Set Over-representation Analysis	62
2.3.3	Clustering	62
2.3.4	Heatmap	63
2.3.5	Modeling and Simulations	63
2.3.5.1	Receiver Operating Characteristic (Performance) . . .	64
2.3.6	Resampling Analysis	64
2.4	Pathway Structure Methods	65
2.4.1	Network and Graph Analysis	65

2.4.2	Sourcing Graph Structure Data	66
2.4.3	Constructing Pathway Subgraphs	67
2.4.4	Network Analysis Metrics	67
2.5	Implementation	68
2.5.1	Computational Resources and Linux Utilities	68
2.5.2	R Language and Packages	69
2.5.3	High Performance and Parallel Computing	72
3	Methods Developed During Thesis	74
3.1	A Synthetic Lethal Detection Methodology	74
3.2	Synthetic Lethal Simulation and Modelling	77
3.2.1	A Model of Synthetic Lethality in Expression Data	77
3.2.2	Simulation Procedure	81
3.3	Detecting Simulated Synthetic Lethal Partners	84
3.3.1	Binomial Simulation of Synthetic lethality	84
3.3.2	Multivariate Normal Simulation of Synthetic lethality	86
3.3.2.1	Multivariate Normal Simulation with Correlated Genes	89
3.3.2.2	Specificity with Query-Correlated Pathways	96
3.3.2.3	Importance of Directional Testing	96
3.4	Graph Structure Methods	98
3.4.1	Upstream and Downstream Gene Detection	98
3.4.1.1	Permutation Analysis for Statistical Significance	99
3.4.1.2	Hierarchy Based on Biological Context	100
3.4.2	Simulating Gene Expression from Graph Structures	101
3.5	Customised Functions and Packages Developed	105
3.5.1	Synthetic Lethal Interaction Prediction Tool	105
3.5.2	Data Visualisation	106
3.5.3	Extensions to the iGraph Package	109
3.5.3.1	Sampling Simulated Data from Graph Structures	109
3.5.3.2	Plotting Directed Graph Structures	109
3.5.3.3	Computing Information Centrality	110
3.5.3.4	Testing Pathway Structure with Permutation Testing	110
3.5.3.5	Metapackage to Install iGraph Functions	111
4	Synthetic Lethal Analysis of Gene Expression Data	112
4.1	Synthetic Lethal Genes in Breast Cancer	113
4.1.1	Synthetic Lethal Pathways in Breast Cancer	115
4.1.2	Expression Profiles of Synthetic Lethal Partners	116
4.1.2.1	Subgroup Pathway Analysis	119
4.2	Comparing Synthetic Lethal Gene Candidates	122
4.2.1	Primary siRNA Screen Candidates	122
4.2.2	Comparison with Correlation	123
4.2.3	Comparison with Primary Screen Viability	125
4.2.4	Comparison with Secondary siRNA Screen Validation	126
4.2.5	Comparison to Primary Screen at Pathway Level	128
4.2.5.1	Resampling Genes for Pathway Enrichment	130

4.2.6	Integrating Synthetic Lethal Pathways and Screens	133
4.3	Metagene Analysis	135
4.3.1	Pathway Expression	136
4.3.2	Somatic Mutation	138
4.3.3	Synthetic Lethal Pathway Metagenes	142
4.3.4	Synthetic Lethality in Breast Cancer	143
4.4	Replication in Stomach Cancer	144
4.5	Discussion	145
4.5.1	Strengths of the SLIPT Methodology	145
4.5.2	Synthetic Lethal Pathways for E-cadherin	146
4.5.3	Replication and Validation	148
4.5.3.1	Integration with siRNA Screening	148
4.5.3.2	Replication across Tissues	149
4.6	Summary	149
5	Synthetic Lethal Pathway Structure	151
5.1	Synthetic Lethal Genes in Reactome Pathways	151
5.1.1	The PI3K/AKT Pathway	152
5.1.2	The Extracellular Matrix	154
5.1.3	G Protein Coupled Receptors	157
5.1.4	Gene Regulation and Translation	157
5.2	Network Analysis of Synthetic Lethal Genes	158
5.2.1	Gene Connectivity and Vertex Degree	159
5.2.2	Gene Importance and Centrality	160
5.2.2.1	Information Centrality	160
5.2.2.2	PageRank Centrality	162
5.3	Relationships between Synthetic Lethal Genes	164
5.3.1	Hierarchical Pathway Structure	164
5.3.1.1	Contextual Hierarchy of PI3K	164
5.3.1.2	Testing Contextual Hierarchy of Synthetic Lethal Genes	164
5.3.2	Upstream or Downstream Synthetic Lethality	168
5.3.2.1	Measuring Structure of Candidates within PI3K	168
5.3.2.2	Resampling for Synthetic Lethal Pathway Structure . .	170
5.4	Discussion	172
5.5	Summary	174
6	Simulation and Modeling of Synthetic Lethal Pathways	176
6.1	Comparing Synthetic Lethal Detection Methods	177
6.1.1	Performance of SLIPT and χ^2 across Quantiles	178
6.1.1.1	Correlated Query Genes affects Specificity	181
6.1.2	Alternative Synthetic Lethal Detection Strategies	183
6.1.2.1	Correlation for Synthetic Lethal Detection	184
6.1.2.2	Testing for Bimodality with BiSEp	185
6.2	Simulations with Graph Structures	186
6.2.1	Performance over a Graph Structure	187
6.2.1.1	Simple Graph Structures	187

6.2.1.2	Constructed Graph Structures	188
6.2.2	Performance with Inhibitions	192
6.2.3	Synthetic Lethality across Graph Structures	198
6.2.4	Performance within a Simulated Human Genome	201
6.3	Simulations in More Complex Graph Structures	206
6.3.1	Simulations over Pathway-based Graphs	207
6.3.2	Pathway Structures in a Simulated Human Genome	210
6.4	Discussion	213
6.4.1	Simulation Procedure	213
6.4.2	Comparing Methods with Simulated Data	214
6.4.3	Design and Performance of SLIPT	215
6.4.4	Simulations from Graph Structures	217
6.5	Summary	218
7	Discussion	220
7.1	Synthetic Lethality and <i>CDH1</i> Biology	220
7.1.1	Established Functions of <i>CDH1</i>	221
7.1.2	The Molecular Role of <i>CDH1</i> in Cancer	221
7.2	Significance	222
7.2.1	Synthetic Lethality in the Genomic Era	222
7.2.2	Clinical Interventions based on Synthetic Lethality	224
7.3	Future Directions	225
7.3.1	Refinements Synthetic Lethality Prediction Methods	225
7.3.1.1	Wider Use of Synthetic Lethality Prediction	225
7.3.2	Validation of Synthetic Lethal Genes and Pathways	225
7.3.2.1	Pre-clinical and Clinical Testing	225
7.3.3	Application to Further Genes and Pathways	225
7.4	Conclusion	226
	References	228
A	Sample Correlation	51
B	Replicate Samples in TCGA Breast	53
C	Software Used for Thesis	57
D	Secondary Screen Data	66
E	Mutation Analysis in Breast Cancer	68
F	Expression Analysis in Stomach Cancer	77
G	Mutation Analysis in Stomach Cancer	78

List of Figures

1.1	Synthetic genetic interactions	26
1.2	Synthetic lethality in cancer	30
2.1	Read count density	59
2.2	Read count sample mean	59
3.1	Framework for synthetic lethal prediction	75
3.2	Synthetic lethal prediction adapted for mutation	76
3.3	A model of synthetic lethal gene expression	78
3.4	Modeling synthetic lethal gene expression	79
3.5	Synthetic lethality with multiple genes	80
3.6	Simulating gene function	82
3.7	Simulating synthetic lethal gene function	82
3.8	Simulating synthetic lethal gene expression	83
3.9	Performance of binomial simulations	85
3.10	Comparison of statistical performance	85
3.11	Performance of multivariate normal simulations	87
3.12	Simulating expression with correlated gene blocks	90
3.13	Simulating expression with correlated gene blocks	91
3.14	Synthetic lethal prediction across simulations	92
3.15	Performance with correlations	93
3.16	Comparison of statistical performance with correlation structure	94
3.17	Performance with query correlations	95
3.18	Statistical evaluation of directional criteria	96
3.19	Performance of directional criteria	97
3.20	Simulated graph structures	101
3.21	Simulating expression from a graph structure	103
3.22	Simulating expression from graph structure with inhibitions	104
3.23	Demonstration of violin plots with custom features	107
3.24	Demonstration of annotated heatmap	107
3.25	Simulating graph structures	110
4.1	Synthetic lethal expression profiles of analysed samples	118
4.2	Comparison of SLIPT to siRNA	122
4.3	Compare SLIPT and siRNA genes with correlation	123
4.4	Compare SLIPT and siRNA genes with correlation	124
4.5	Compare SLIPT and siRNA genes with viability	125

4.6	Compare SLIPT genes with siRNA viability	126
4.7	Resampled intersection of SLIPT and siRNA candidates	130
4.8	Pathway metagene expression profiles	137
4.9	Expression profiles for constituent genes of PI3K	139
4.10	Expression profiles for estrogen receptor related genes	140
4.11	Somatic mutation against the PI3K metagene	141
5.1	Synthetic Lethality in the PI3K Cascade	153
5.2	Synthetic Lethality in the Elastic Fibre Formation Pathway	155
5.3	Synthetic Lethality in the Fibrin Clot Formation	156
5.4	Synthetic Lethality and Vertex Degree	159
5.5	Synthetic Lethality and Centrality	162
5.6	Synthetic Lethality and PageRank	163
5.7	Hierarchical Structure of PI3K	165
5.8	Hierarchy Score in PI3K against Synthetic Lethality in PI3K	166
5.9	Structure of Synthetic Lethality in PI3K	168
5.10	Structure of Synthetic Lethality Resampling in PI3K	169
6.1	Performance of χ^2 and SLIPT across quantiles	179
6.2	Performance of χ^2 and SLIPT across quantiles with more genes	180
6.3	Performance of χ^2 and SLIPT across quantiles with query correlation	181
6.4	Performance of χ^2 and SLIPT across quantiles with query correlation and more genes	183
6.5	Performance of negative correlation and SLIPT	185
6.6	Simple graph structures	188
6.7	Performance of simulations on a simple graph	189
6.8	Performance of simulations is similar in simple graphs	190
6.9	Performance of simulations on a pathway	191
6.10	Performance of simulations on a simple graph with inhibition	193
6.11	Performance is higher on a simple inhibiting graph	195
6.12	Performance of simulations on a constructed graph with inhibition	196
6.13	Performance is affected by inhibition in graphs	197
6.14	Detection of Synthetic Lethality within a Graph Structure with Inhibitions	199
6.15	Performance of simulations including a simple graph	203
6.16	Performance on a simple graph improves with more genes	204
6.17	Performance on an inhibiting graph improves with more genes	205
6.18	Performance of simulations on the PI3K cascade	209
6.19	Performance of simulations including the PI3K cascade	211
6.20	Performance on pathways improves with more genes	212
A.1	Correlation profiles of removed samples	51
A.2	Correlation analysis and sample removal	52
B.1	Replicate excluded samples	53
B.2	Replicate samples with all remaining	54
(a)	Remaining triplet	54
(b)	Remaining triplet	54

(c)	Remaining triplet	54
(d)	Remaining paired samples	54
(e)	Remaining paired samples	54
(f)	Remaining paired samples	54
B.3	Replicate samples with some excluded	55
(a)	Remaining	55
(b)	Compare with excluded	55
(c)	Compare with excluded	55
(d)	Remaining	55
(e)	Compare with excluded	55
(f)	Compare with excluded	55
(g)	Remaining	55
(h)	Compare with excluded	55
(i)	Compare with excluded	55
B.3	Replicate samples with some excluded	56
(j)	Remaining	56
(k)	Compare with excluded	56
(l)	Compare with excluded	56
(m)	Compare with excluded	56
(n)	Compare with excluded	56
E.1	Synthetic lethal expression profiles of analysed samples	70
E.2	Comparison of mtSLIPT to siRNA	72
G.1	Synthetic lethal expression profiles of stomach samples	80
G.2	Comparison of mtSLIPT in stomach to siRNA	82

List of Tables

1.1	Methods for Predicting Genetic Interactions	37
1.2	Methods for Predicting Synthetic Lethality in Cancer	38
1.3	Methods used by Wu <i>et al.</i> (2014)	40
2.1	Excluded Samples by Batch and Clinical Characteristics.	58
2.2	Computers used during Thesis	69
2.3	Linux Utilities and Applications used during Thesis	69
2.4	R Installations used during Thesis	70
2.5	R Packages used during Thesis	70
2.6	R Packages Developed during Thesis	72
4.1	Candidate synthetic lethal gene partners of <i>CDH1</i> from SLIPT	114
4.2	Pathways for <i>CDH1</i> partners from SLIPT	116
4.3	Pathway composition for clusters of <i>CDH1</i> partners from SLIPT	120
4.4	Analysis of variance (ANOVA) for Synthetic Lethality and Correlation with <i>CDH1</i>	124
4.5	Comparing SLIPT genes against secondary siRNA screen in breast cancer	127
4.6	Pathway composition for <i>CDH1</i> partners from SLIPT and siRNA screen- ing	129
4.7	Pathways for <i>CDH1</i> partners from SLIPT	132
4.8	Pathways for <i>CDH1</i> partners from SLIPT and siRNA primary screen .	134
4.9	Candidate synthetic lethal metagenes against <i>CDH1</i> from SLIPT	143
5.1	ANOVA for Synthetic Lethality and Vertex Degree	160
5.2	ANOVA for Synthetic Lethality and Information Centrality	162
5.3	ANOVA for Synthetic Lethality and PageRank Centrality	164
5.4	ANOVA for Synthetic Lethality and PI3K Hierarchy	167
5.5	Resampling for pathway structure of synthetic lethal detection methods	171
C.1	R Packages used during Thesis	57
D.1	Comparing SLIPT genes against Secondary siRNA Screen in breast cancer	66
D.2	Comparing mtSLIPT genes against Secondary siRNA Screen in breast cancer	67
D.3	Comparing SLIPT genes against Secondary siRNA Screen in stomach cancer	67
E.1	Candidate synthetic lethal genes against E-cadherin from mtSLIPT . .	68

E.2	Pathways for <i>CDH1</i> partners from mtSLIPT	69
E.3	Pathway composition for clusters of <i>CDH1</i> partners from mtSLIPT . .	71
E.4	Pathway composition for <i>CDH1</i> partners from mtSLIPT and siRNA . .	73
E.5	Pathways for <i>CDH1</i> partners from mtSLIPT	74
E.6	Pathways for <i>CDH1</i> partners from mtSLIPT and siRNA primary screen	75
E.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from mtSLIPT . .	76
G.1	Candidate synthetic lethal genes against E-cadherin from mtSLIPT in stomach cancer	78
G.2	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach cancer	79
G.3	Pathway composition for clusters of <i>CDH1</i> partners in stomach mtSLIPT	81
G.4	Pathway composition for <i>CDH1</i> partners from mtSLIPT and siRNA . .	83
G.5	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach cancer	84
G.6	Pathways for <i>CDH1</i> partners from mtSLIPT in stomach and siRNA screen	85
G.7	Candidate synthetic lethal metagenes against <i>CDH1</i> from mtSLIPT in stomach cancer	86

Glossary

bioinformatics	Statistical or computational approaches to biological data or research tools.
bisulfite-Seq	Methylome data from sequencing bisulfite treated DNA.
CAGE-Seq	Transcriptome data from cap analysis of gene expression.
E-cadherin	Epithelial cadherin (calcium-dependent adhesion), a cell-adhesion protein encoded by the tumour suppressor gene <i>CDH1</i> .
epigenome	An analysis of epigenetic modifications of all genes in the genome.
exome	An approach or technology designed to generate or use data from all genes in the genome.
genomics	An approach or technology designed to generate or use data from all genes in the genome.
metabolome	An analysis of all the metabolites and enzymes in the cell.
metagenomics	An analysis of all the genes and genomes in a community.
microRNA	Short RNA molecules generally regarded to regulate gene expression by binding to mRNA.
omics	A rationale for applying molecular studies across all of the genes in the genome or biomolecules in the cell.
Pan cancer	Study or analysis of cancers across tissue of origin.
pleiotropy	A gene which has multiple biological functions.

proteome	An analysis of all the proteins expressed from the genome.
RNA-Seq	Transcriptome data from sequencing RNA.
Sanger	A dideoxy chain termination method for DNA sequencing (named after Fred Sanger).
synthetic lethal	Genetic interactions where inactivation of multiple genes is inviable (or deleterious) when they are viable if inactivated separately.
transcriptome	An analysis of all the genes expressed in the genome.

Acronyms

ANOVA	Analysis of Variance.
AUROC	Area under the receiver operating characteristic (curve).
BiSEp	Bimodal Subsetting Expression.
CCLE	Cancer Cell Line Encyclopaedia.
cDNA	Complementary deoxyribonucleic acid (from mRNA).
ChIP-Seq	Chromatin immunoprecipitation sequencing.
COSMIC	Catalogue Of Somatic Mutations In Cancer.
DAISY	Data mining synthetic lethal identification pipeline.
DDBJ	DNA Data Bank of Japan.
DNA	Deoxyribonucleic acid.
EMBL	European Molecular Biology Laboratory.
EMT	Epithelial-mesenchymal transition.
ENA	The European Nucleotide Archive.
GEO	Gene Expression Omnibus.
GO	Gene Ontology.
HDAC	Histone deacetylase.
HDGC	Hereditary diffuse gastric cancer.
HLRCC	Hereditary leiomyomatosis and renal cell carcinoma.
ICGC	International Cancer Genome Consortium.
InDel	Insertion or deletion (in DNA sequence).
JAK	Janus kinase.
lncRNA	Long non-coding ribonucleic acid.

miRNA	microRNA.
mRNA	Messenger ribonucleic acid.
NCBI	National Center for Biotechnology Information (in the USA).
NCI	National Cancer Institute (in the USA).
NGS	Next-generation sequencing.
NHGRI	National Human Genome Research Institute (in the USA).
NIG	National Institute of Genetics (in Japan).
NIH	National Institutes of Health (in the USA).
PCR	Polymerase chain reaction.
PI3K	Phosphoinositide 3-kinase.
qPCR	Quantitative (real-time) polymerase chain reaction.
RFLP	Restriction fragment length polymorphism.
RNA	Ribonucleic acid.
RNAi	Ribonucleic acid interference.
RRBS	Reduced representation bisulfite sequencing.
SGI	synthetic genetic interaction.
siRNA	Short interfering ribonucleic acid.
SLIPT	Synthetic lethal interaction prediction tool.
SNP	Single nucleotide polymorphism.
TCGA	The Cancer Genome Atlas (genomics project).

Chapter 1

Introduction and Literature Review

1.1 Cancer Research in the Post-Genomic Era

Genomics technologies have the potential to vastly impact upon various areas including health and cancer medicine. Considering the progress in recent genomics research, this technology and the findings from it have considerable potential for significant impacts in the clinic and wider applications of genetics either directly or by enabling more focused genetics research on candidates selected from genomics or bioinformatics analysis. The completion of the draft Human Genome (Lander *et al.*, 2001) marks a major accomplishment in genetics research and raises new challenges to utilise this genomic scale information effectively. Technologies in this area have rapidly developed since completion of the human genome project and many global large-scale projects have expanded upon the human genome, to populations (1000 Genomes, 2010), to cancers (Dickson, 1999; Zhang *et al.*, 2011), and to deeper functional understanding (Kawai *et al.*, 2001; ENCODE, 2004). However, impact on the clinic has been slower than initially anticipated following the completion of the “draft” genome with genomics technologies yet to become widely adopted in healthcare and oncology. Here we outline the genomics technologies and bioinformatics approaches which have led to availability of genomics data and techniques used in this thesis and potential for applications in cancer research or the clinic in the future.

1.1.1 Cancer as a Global Health Concern

Cancer is a class of diseases involving malignant cellular growth, invasion of tissues, and spread to other organs. While there are also environmental factors, most cancers occur more frequently with age and family history. Accordingly, genetics has become widely acknowledged as having an important role in cancer risk (in addition to environmental

factors). Cancers arise from dysregulated cellular growth or differentiation from stem cells. These can occur through genetic mutations or alterations in gene regulation or expression.

Cancers are a major global health concern, being the second leading cause of death globally (WHO, 2017), with an estimated annual incidence of 14.1 million cases and annual mortality of 8.2 million people (Ferlay *et al.*, 2015). Breast and stomach cancers are among the 5 most frequent cancers globally, with breast cancer affecting women more than other cancer tissue types. Breast cancer has an estimated annual incidence of 1.6 million cases and mortality of 520 thousand people. Stomach cancer has an estimated annual incidence of 950 thousand cases and a mortality of 723 thousand people. Cancer is also a major health concern here in New Zealand, with 19.1 thousand people (including 2.5 thousand cases of breast cancer and 370 cases of stomach cancer) diagnosed annually (Hanna, 2003), among the highest incidence (age-standardised per capita) of cancer in the world (Ferlay *et al.*, 2015).

While the genetic contribution to cancer risk and many of the molecular changes occurring in cancers are widely acknowledged (ASCO, 2017; Cancer Research UK, 2017; Cancer Society of NZ, 2017), the majority of these findings have yet to impact on clinical practice. Diagnostics are traditionally based on pathological examination of tissue samples where histological staining for cell type, biomolecules and biomarkers continue to be widely used, although genetic and biochemical markers are being adopted for some cancer types. In general, the current standard of care includes surgery, radiation, and cytotoxic chemotherapy, depending on whether the cancer is localised or has become systemic (via metastasis) and spread to other organ systems. These approaches can be effective against certain cancers, particularly in early stage cancer or in patients with particular subtypes (such as acute myeloid leukaemia) which respond well to modern treatment regimens. Thus early diagnosis is important to patient survival and quality of life. National screening programs (which prioritise patients with a high risk of cancer) therefore aim to diagnose cancers early and subtypes more accurately. Therefore identification of patients with genetic variants or family histories (for inclusion in national databases) for high risk of particular cancers is an important health issue, particularly where effective interventions exist if these cancers are diagnosed early. Thus high risk individuals being regularly monitored for some cancers are sometimes offered preventative surgery or treatment for pre-cancerous tissue (Guilford *et al.*, 2010; Scheuer *et al.*, 2002).

Chemotherapy is a last-resort treatment for many advanced stage (systemic) cancers which is designed to inhibit the growth and spread of cancer throughout the body by targeting rapidly growing cells. However, this approach often has severe adverse effects, a narrow therapeutic window, and is not suitable for chemopreventative application in many cases (Kaelin, Jr, 2009). Since surveillance preventative surgery (removing the tissue at risk of cancer) is not completely effective at preventing cancers and may impact on quality of life, depending on the cancer tissue types they are at risk of, alternative treatment strategies based on molecular biology and other fields are being investigated. These alternatives include immunological, endocrine, and targeted therapeutics, with a particular interest in treatments with specificity against cancer cells and wider applications (i.e., tolerable effective doses in applications as a chemopreventative or against advanced stage cancers).

1.1.1.1 The Genetics and Molecular Biology of Cancers

Cancers involve dysregulation of genes with both somatic mutations or regulatory disruptions which accumulate during a patient’s lifetime and germline mutations which predispose individuals to high-risk early onset cancers (American Cancer Society, 2017; Guilford *et al.*, 1998; NCI, 2015). Cancer is widely viewed to be a genetic disease due to these familial cancer syndromes, hereditary risk factors, and the molecular changes occurring in cancers, including numerous cancer genes which have been identified Stratton *et al.* (2009); Vogelstein *et al.* (2013). Cancer genes are generally classified into two classes: “oncogenes” which are activated in cancers, driving tumour growth and invasion, or “tumour suppressors” which are inactivated in cancers, removing cellular regulation and genomic maintenance functions. The mutations which cause cancers accumulate with age and have been suggested to be inevitably coupled with aging due to the association of cancer incidence with the stem cell divisions in which mutations could occur across tissue types (Tomasetti and Vogelstein, 2015).

Hanahan and Weinberg (2000) identified several key molecular and cellular traits shared across most cancers as a rational approach to the complex changes that occur in cancer initiation and progression due to common molecular machinery underlying all cells. A cancer cell must possess limitless replication potential, modulate growth signals to grow indefinitely, and gain invasive or metastatic capabilities. In addition, cancers must evade apoptosis, the immune system, and sustain angiogenesis and energy metabolism in order to survive (Hanahan and Weinberg, 2000, 2011). In order to achieve this, cancer cells undergo changes to their genomes and the surrounding cells to create a tumour microenvironment. Thus genomic instability has a key role in the

survival and proliferation of cancer cells and the progression of further disease, as these malignant characteristics are acquired. Identifying the mechanisms of these acquired traits and the underlying genetic mutation or dysregulation behind them, such as E-cadherin mutation in metastasis or p53 mutation in genomic instability (Hanahan and Weinberg, 2000), will be an important step in understanding and inhibiting cancer with the next generation of genomically-informed treatments.

Molecular biological processes have particular importance in characterising breast cancers. Gene expression and regulatory signals confer cell identity and response to the environment. Therefore gene expression has been investigated with microarray technologies Perou *et al.* (2000), with “intrinsic subtypes” identified characterised by estrogen receptor, *HER2*, and basal, epithelial signalling. The expression profiles were similar across independent samples of the same tumour and between primary and metastatic tumours of the same patient. Thus expression profiles represent the molecular state of a tumour rather than the sample and the molecular configuration of the cells regulation is carried through the cellular lineage of during metastasis preserving the molecular subtype. These molecular intrinsic subtypes “luminal A”, “luminal B”, “HER2-enriched”, “basal-like”, and “normal-like” have been replicated across microarray studies (Hu *et al.*, 2006), with their relevance to prognosis (including predicting survival and response to neoadjuvant chemotherapy) demonstrated and a 50-gene subtype predictor from microarray and quantitative PCR (qPCR) analysis has been provided (Parker *et al.*, 2009; Sørlie *et al.*, 2001). This has been further updated with the “claudin-low” subtype (Herschkowitz *et al.*, 2007) and stimulated further investigations into subtyping of breast cancers by molecular properties.

Despite differences in subtyping performed by different research groups and companies, there is widespread agreement that distinguishing luminal, HER2-enriched, and triple negative tumours can be performed with expression profiles and have value in our understanding of cancer progression and prognostic importance for patients Dai *et al.* (2015). High-throughput technologies have the potential to enable such subtyping on a vast scale in discovery of further subtypes in breast cancer or other diseases and in identification of these subtypes along with mutations in routine clinical diagnostic and prognostic testing. The “Pan cancer” approaches by the cancer genome atlas project (as discussed in more detail in Section 1.1.5.1.1) expand on the importance of molecular differences between cancers by examining molecular profiles across cancer tissue types (Weinstein *et al.*, 2013).

The molecular variability of cancer has also been approached rationally at a pathway level with patients subgroups activating different molecular pathways reflecting differences in disease mechanisms (Gatza *et al.*, 2010). A robust approach to measuring pathway activation in cancer is with a “metagene” which gives a consistent signal as a consensus of expression across genes even if they are inversely correlated (Anjomshoaa *et al.*, 2008; Huang *et al.*, 2003; Nagalla *et al.*, 2013). These are derived from the first principal component or eigenvector of a singular matrix decomposition, capturing the the most consistent variation across genes in a pathway or gene signature. Gatza *et al.* (2010) used gene signatures for 18 cellular pathways in breast cancer to define subtypes with distinct molecular pathway activity. In a meta-analysis of Affymetrix microarray expression data for 1,143 samples and 50 cell lines, unsupervised hierarchical clustering robustly defined subtypes with common homogeneous pathway activity despite variation in the specific mutations giving rise to them. These subtypes with shared pathway activity have similar molecular characteristics (such as DNA copy number), clinical properties and prognosis, building upon the intrinsic subtypes (Parker *et al.*, 2009) and providing a functional interpretation for molecular stratification (Gatza *et al.*, 2010). The pathway-based subtypes often correspond to intrinsic subtypes (Gatza *et al.*, 2010, 2014) and provide finer molecular stratification such as environmental stress response (to hypoxia within HER2-enriched cancers) (Gatza *et al.*, 2011) and have pathway-specific DNA copy number variation or essential genes (Gatza *et al.*, 2014). Gatza *et al.* (2014) extend these analyses include 52 pathway signatures from previous publications in breast cancer, replicating known characteristics (such as hormone re) of each subtype and identifying novel subtype-specific driver genes of proliferation by analysis of microarray expression from 476 from The Cancer Genome Atlas (TCGA). In addition to distinct biological functions driving growth of breast cancer subtypes, these molecular subtypes provide a rational approach based on molecular properties to cancer treatment with combination and targeted therapies (Gatza *et al.*, 2010, 2014; Hanahan and Weinberg, 2000).

Cancer is a major health concern with a well-established genetic contribution, in risk and in the molecular changes occurring during progression (Stratton *et al.*, 2009). Many genes have been discovered to be important in different cancers with molecular differences between cancers, including alterations across the genome, being of clinical importance. As such cancers were among the first samples investigated with genomics following the sequencing of the human genome Dickson (1999) and continue to be the subject of genomics and bioinformatics investigations.

1.1.2 The Human Genome Revolution

The advent of the Human Genome sequence (Lander *et al.*, 2001) has transformed genetics research including the study of health and disease (Lander, 2011; Peltonen and McKusick, 2001). Systematic, unbiased studies across all of the genes in the genome are viable in unprecedented ways. The successful undertaking of such an international scientific megaproject has set an example for numerous initiatives to follow, including many genomics investigations expanding to species, to the functional, or to the population level (Collins *et al.*, 2003). These projects serve as an excellent resource for genetics research globally, particularly for cancers where genomics investigation have been widely applied to different tissues across molecular profiles Bamford *et al.* (2004); Weinstein *et al.* (2013); Zhang *et al.* (2011) . Genome sequencing technologies continue to improve, decrease in price, and become increasingly feasible in a wider range of research and clinical applications.

1.1.2.1 The First Human Genome Sequence

The first human genome is a good example of a large-scale genomics project for it's success as an international collaboration and releasing their data as a resource for the wider scientific community (Collins *et al.*, 2003; Lander *et al.*, 2001). This particular project generated significant public interest due to it being a landmark achievement, the first of it's scale, and some controversial findings. Namely, the number of genes discovered (particularly those specific to vertebrates) was much lower than most estimates for a genome of it's size and the number of repetitious transposon elements was very high. Even the figure of 30–40,000 genes given by the original publication is now regarded to be an overestimate (Ezkuirdia *et al.*, 2014; IHGSC, 2004).

Accounting for the “complexity” encoded by the human genome with so few genes has led to investigations into molecular function, expression profiling, and population variation. When announcing the draft genome, Lander *et al.* (2001) conceded that genomic information alone was not sufficient for biological understanding and that many investigations remained to be carried out, with their objective being to share the raw genome data so that it was available for further inquiry rather than interpreting it themselves. While genomics technologies and genomics projects have flourished since then, the need in turn for systematic means of interpreting data of such scale and for the interdisciplinary expertise to do so has only grown.

1.1.2.2 Impact of Genomics

Genomics has stimulated investigations into many of these previously largely explored areas of functional genetics and thus been of immense value in genetics research, attracting high expectations for further applications. Genomics research created widespread anticipation for potential applications in healthcare, agriculture, ecology, conservation, and evolutionary biology despite few of these being realised yet.

Cancer research is an area of particularly high expectations for the clinical impact of genomics in oncology. Genomics technologies have potential applications across cancer diagnostics, prognosis, management, and developing treatment. Cancers often involve genetic mutation or dysregulated gene expression which can be detected in a genome or transcriptome with potential to improve patient care. While direct impact of genomics on the clinic has been limited, compared to initial expectations following the publication of the human genome, diagnostic cancer genes and therapeutic targets identified with genomics research have begun to be introduced in the clinic (Stratton *et al.*, 2009).

1.1.3 Technologies to Enable Genetics Research

1.1.3.1 DNA Sequencing and Genotyping Technologies

Genotyping was once commonly performed on variable regions of the genome with restriction fragment length polymorphism (RFLP) or repetitious microsatellite regions. These exploited sequence variation at target sites of restriction enzymes or measured the length of repetitious regions, using polymerase chain reaction (PCR), restriction enzymes, and gel electrophoresis to measure deoxyribonucleic acid (DNA) genotypes at particular sites. This is laborious and limited to well characterised variable regions of the genome, generally genes or nearby marker regions.

The Sanger (dideoxy) chain termination method (Sanger and Coulson, 1975) enabled DNA sequencing and genotyping at a widespread scale, being less technically difficult than the Maxam-Gilbert sequencing by degradation method (Gilbert and Maxam, 1973; Maxam and Gilbert, 1977), which required more radioactive and toxic reactants. The Sanger methodology has relatively long read length (particularly compared to early versions of more recent technologies), with read lengths of 500–700 base pairs accurately sequenced in most applications, usually following targeted amplification with PCR. Sanger sequencing by gel electrophoresis takes around 6–8 hours and has been further refined with the “capillary” approach to 1–3 hours and requiring less input DNA and reactants. The capillary approach has been scaled up to run in parallel from

a 96 well plate, at 166 kilobases per hour. The 96 well parallel capillary method was one of the main innovations which made the first Human Genome Project feasible and was used throughout (Lander *et al.*, 2001). Due to the quality of the Sanger sequence reads and low cost, it is still widely used in smaller scale applications, clinical testing, and to validate the findings of newer approaches.

1.1.3.2 Microarrays and Quantitative Technologies

Real-time or qPCR is another adaptation of genetic technologies to quantitatively study nucleic acids, often reverse transcribed “deoxyribonucleic acid (cDNA)” or messenger “messenger ribonucleic acid (mRNA)” to measure (relative) gene expression or transcript abundance. While numerous quality control measures are required to correctly interpret a qPCR experiment, these have similarly become widely adopted and are still used for smaller scale experiments and as a “gold standard” for measuring gene expression (Adamski *et al.*, 2014). This also represents a shift in the application of qPCR and sequencing technology, where the primary interest is quantifying the amount of input material (by the rate of amplification to a certain level) rather than the qualitative nature of the sequence itself. The more recent technologies of microarrays and RNA-Seq have similarly embraced this application to quantify DNA copy number, ribonucleic acid (RNA) expression, and DNA methylation levels. Due to results of comparable or arguably better quality from these newer technologies (Beck *et al.*, 2016; Git *et al.*, 2010; McCourt *et al.*, 2013; Robin *et al.*, 2016), this “gold standard” status has begun to come under scrutiny.

Microarrays represent a truly high-throughput molecular technique, reducing the cost, time, and labour required to study molecular factors such as genotype, expression, or methylation across many genes, making it feasible to do so over a statistically meaningful number of samples. Microarrays are manufactured with probes which measure binding of particular nucleotide sequences to either quantitatively detect the presence of a sequence such as a single nucleotide polymorphism (SNP) or quantify DNA copy number, gene expression, or DNA CpG methylation. Microarray technologies have popularised “genome scale” studies of genetic variation and expression.

In addition to being more versatile and higher-throughput than PCR based techniques, microarrays are considered cost-effective, particularly when scaled up to a large number of probes. They are also available with established gene panels or customised probes from a number of commercial manufacturers. These remained popular during the introduction of newer technologies due to reliability and relatively lower cost, especially in large-scale projects involving many samples. However, microarrays have

issues with signal-to-noise ratio, with both sensitivity to low nucleic acid abundance and “saturation” of probes at high abundance, edge effects, and requiring more starting material than qPCR. Thus qPCR is still used for many small gene panel studies.

1.1.3.3 Massively Parallel “Next Generation” Sequencing

Similar to microarrays, the introduction of massively parallel sequencing technologies have further expanded the availability of high-throughput molecular studies to researchers, with corresponding availability of genomics data from these studies. This “Next-Generation Sequencing” (NGS) expands not only gene expression studies (compared to microarrays) but extends to genome sequencing *de novo* for previously unknown genome and transcriptome sequences at an unprecedented scale. This has been a particularly important technological revolution in genomics, as the cost and time of genome sequencing has dropped dramatically and enabled sequencing projects of far more samples and applications beyond the Human Genome Project. Particularly, when dealing with variants in a species with an existing reference sequence such as humans, where there is a low computational cost of mapping to a reference compared to a genome assembly. However, the cost of sequencing (RNA-Seq) for gene expression or DNA methylation studies is still considerably higher than a microarray study (limiting feasible sample sizes).

Compared with arrays, NGS studies have additional challenges, particularly regarding large data and compute requirements to handle the raw output data. Compared with the established methods to analyse microarray data, handling NGS data can be more technically difficult. While methods developed for analysing microarray data can be repurposed for sequence analysis in many cases, more bioinformatics expertise is required particularly to handle the raw read data and changing approaches for various developments in sequencing technologies. One of the main computational challenges is the assembly of reads or mapping to a reference genome due to the inherently small reads of most NGS technologies compared to the Sanger methodology. Furthermore, there are fewer software releases and best practices established specifically for RNA-Seq data, thus many analyses are still conducted with customised analysis approaches and command-line tools. Compared to existing graphical tools or pipelines for microarray analysis, this is a more active technology for bioinformatics research where many applications of genomics data have yet to be explored.

However, the methodology itself has challenges with the sample preparation, requiring a relatively high quantity of input material and “contamination” with over abundant ribosomal rRNA taking up the majority of the sequencing if not purified

correctly. This abundance of rRNA is a particularly important issue in microarray and RNA experiments in Eukaryotes where it is commonplace to target the mRNA by binding to the poly-A tail (RNA-Seq) or 5' cap (CAGE-Seq). However, this has the potential to exclude miRNA (miRNA) and long non-coding ribonucleic acid (lncRNA) of interest unless the sample is prepared specifically to study these. Similarly capturing a subsection of the genome for exome analysis or reduced representation bisulfite sequencing (RRBS), focuses on sequencing DNA sequences and methylation levels of CpG sites near known genes to reduce cost, noise, and incidental findings.

In many cases, the benefits of NGS technologies over microarrays still outweigh the additional cost. NGS technologies have the advantage of greater potential accuracy and sensitivity than microarrays, depending on the sequencing depth or “coverage”, theoretically sensitive down to the exact number of molecules for each transcript. NGS experiments are regarded as “reproducible” with no need for technical replicates, although these are still performed for a subset of samples in many projects for quality assurance purposes. NGS has a wider dynamic range than microarrays and is able to detect SNPs, insertions or deletions, and splice variants in addition to quantifying DNA copy number or transcript abundance. NGS scales to all genes and beyond for these molecular applications without having to design new probes as required for a microarray. Thus NGS technologies are not limited to genes with already characterised sequence or functions, do not need to be updated with new probes for each genome annotation release, and do not require a reference genome at all for new species. A “transcriptome” can be assembled *de novo* for an expression study in any organism by sequencing the mRNA extracted from a cell.

1.1.3.3.1 Molecular Profiling with Genomics Technology

NGS is highly adaptable to different applications: DNA sequencing (whole genome or exome), DNA methylation (bisulfite-Seq), RNA-Seq, miRNA, lncRNA, or chromatin immunoprecipitation sequencing (ChIP-Seq). RNA-Seq of the transcriptome is a common adaptation where RNA is reverse transcribed and sequenced from the resulting cDNA. This is utilised to quantify the levels of RNA and identify which regions of DNA are expressed. Similar bisulfite treatment converts cytosine residues to uracil (sequenced as thymidine), sparing methylated cytosine enabling it to be distinguished with bisulfite-Seq for high-throughput detection of the notable epigenetic mark and is a common procedure to generate an epigenome. Subsets of the nucleic acid may be extracted for sequencing such as the coding regions of DNA (for the “exome”), the

mRNA 5' cap (CAGE-Seq), mRNA 3' poly-A tail (RNA-Seq), microRNA, or an enriched subset of variable regions for DNA sequencing (“genotyping by sequencing”) and methylation studies (“reduced-representation bisulfite sequencing”). High-throughput gel and mass spectrometry techniques have been applied to proteins and metabolites to generate the proteome and metabolome respectively. These “omics” technologies are applicable across a wide range of biomolecules in a cell and these “molecular profiles” are produced in many experimental laboratories.

1.1.3.3.2 Sequencing Technologies

Illumina sequencing (developed by Solexa and later acquired by Illumina) was released in 2006. It utilises reversible terminating dyes to sequence by synthesis with a lower accuracy (98%) and read lengths of 150–250bp. Illumina more than makes up for relatively short reads (along with improving the read length of the technology) and low accuracy with high-throughput and cost effectiveness, with a Hi-Seq 4000 platform producing up to 10 billion paired-end reads (1500Gbp) in a run of appropriately 3 days, capable of sequencing 12 human genomes (30× coverage) or 100 human transcriptomes simultaneously (Illumina, 2017). Illumina has further reduced the cost of sequencing with the economies of scale with the Hi-Seq X 10 claiming to produce a human genome (with 30× coverage) for less than US\$1000, the first platform to achieve this long-standing goal in genomics. The high-throughput of Illumina sequencing also makes deep sequencing for high coverage, high quality consensus reads, and sensitive RNA-Seq experiments feasible. Illumina sequencing now has a dominating market share of the NGS technologies. Their Hi-Seq platforms were used in large-scale genomics projects (such as the cancer genome atlas discussed in Section 1.1.5.1) to generate the sequence data used throughout this thesis.

NGS technologies continue to be refined with Illumina (and competitors) continuing to release refined productions, offer additional genomics-based services, and decreases overhead and operating costs to enable a wider range of research projects. As such RNA-Seq for examining the transcriptome of an organisms and for expression studies in diseases is a growing field of research and expression data will continue to be generated for a range of samples in many healthy and diseased tissues. The technology be also be further improved developments in speed and accuracy (such as Ion Torrent platforms) and towards long reads of single molecules (such as Pacific Biosciences, Oxford Nanopore, and Quantum Biosystems Japan).

Due to such benefits of sequencing over previous technologies (and their continued refinement), this thesis has focused on gene expression data generated by RNA-Seq rather by microarrays. RNA-Seq data is widely available as a resource from large-scale cancer genomics projects and methods to make inferences from RNA-Seq experiments could feasibly be applied to many other studies based on these current (or similar future) technologies.

1.1.3.4 Bioinformatics as Interdisciplinary Genomic Analysis

Genomics technologies have given rise to data at a scale previously rarely encountered in molecular biology, making inference with conventional techniques difficult. Computational, Mathematical, and Statistical skills are required to handle this data effectively, in addition to biological background to frame and interpret research questions. Drawing upon these disciplines to handle biological data has become the field of “Bioinformatics”, focusing specifically on making inferences from genomics and high-throughput molecular data or developing the tools to do so. This contrasts with the existing fields of “theoretical” or “computational biology” which existed prior to genomics data, focusing on modelling and simulating aspects of biology without necessarily addressing the genomics data or detecting the phenomena in nature, extending beyond genetics to cell modelling, neuroscience, cancer development, ecology, and evolution.

In practice, many researchers identify with both bioinformatics and computational biology, or draw upon the findings and methods of the other field. This thesis uses many approaches in bioinformatics to biological research questions and established mathematical or bioinformatics resources.

Gene expression analysis is the focus of many bioinformatics research groups, drawing upon statistical approaches to appropriately handle microarray and RNA-Seq data along with making biological inferences from a large number of statistical tests. This presents various challenges from normalising sample data and accounting for batch effects to developing or applying statistical tests tailored to biological hypotheses and testing them at a genome-wide scale, generally across thousands of genes. There are numerous approaches for dealing with these challenges, some of which will be described in Chapter 2.

1.1.4 Follow-up Large-Scale Genomics Projects

A number of projects have attempted to follow up on the human genome project to varying degrees of success. The genomes have since been sequenced for a variety of model organisms, organisms of importance in health, agriculture, metagenomics of

microorganisms (microbiome), ecology and conservation. Genomics projects have also been applied functional genetics (Kawai *et al.*, 2001; ENCODE, 2004) and to human populations with an interest variability between individuals and health or disease risk (HapMap, 2003; 1000 Genomes, 2010).

Genomics databases have also focused on facilitating distribution of genomic data generated by researchers, rather than generating it themselves. GenBank hosted by the National Center for Biotechnology Information (NCBI) in the US, the The European Nucleotide Archive (ENA) hosted by the European Molecular Biology Laboratory (EMBL), and the DNA Data Bank of Japan (DDBJ) hosted by the National Institute of Genetics (NIG) do so by serving as public repositories of DNA sequence data. Gene Expression Omnibus (GEO) (Clough and Barrett, 2016), arrayExpress (Rustici *et al.*, 2013), and caArray (Heiskanen *et al.*, 2014) serve a similar purpose as a resource for gene expression datasets, originally developed for microarray data but RNA-Seq data is now supported by some platforms. They are repositories for researchers to deposit, share, and access gene expression data, serving as a resource to support ongoing research where larger datasets than would were previously accessible for many individual laboratories are available (Rung and Brazma, 2013). These resources cover not only DNA sequence across the genome but also molecular profiles of other factors by adapting genomic sequencing or other high throughput technologies for quantifying gene expression or DNA methylation. Sharing the expression datasets generated in a publication is now required by some journals.

Similarly, international projects and consortiums have begun to release data gathered using common agreed upon protocols in laboratories across the world, often hosting public databases of these themselves, publishing their own investigations into the datasets as they are released, or offering basic searches and analytics of the data via a web portal. These databases include many of the genomics projects discussed above and the cancer-specific projects discussed below. In many ways, the quality, consistency, and accessibility of these international projects has become more appealing than accessing smaller studies, particularly for gene expression datasets where the more recent, larger projects have switched from microarray to RNA-Seq technologies. This distinction will also be discussed later.

1.1.5 Cancer Genomes

The importance of genomics technologies in the future of cancer research was noticed, even in the early days of genomics (Dickson, 1999). The Cancer Genome Project

(CGP) based at Wellcome Trust Sanger Institute in the UK were among the first to launch investigations into cancer after the publication of the Human Genome, using this genome sequence, consensus across the cancer research literature, and sequencing the genes of cancers themselves. Initially, the Sanger Institute set out to sequence 20 genes across 378 samples while the Human Genome project was still ongoing (Collins and Barker, 2007), optimising sequencing and computation infrastructure for a larger project while doing so. The main aim of the Cancer Genome Project was to discover “cancer genes”, those frequently mutated in cancers by comparing the genes of cancer and normal tissue samples, both “oncogenes” and “tumour suppressors” which are activated and inactivated respectively in cancers. This project is ongoing and the UK continues to be involved in international sequencing initiatives and those focused on particular tissue types.

The Sanger Institute also hosts the Catalogue of Somatic Mutations in Cancer (COSMIC, 2016), a database and website of cancer genes. This launched with 66,634 samples and 10,647 mutations from initial investigations into *BRAF*, *HRAS*, *KRAS*, and *NRAS* (Bamford *et al.*, 2004). It has since expanded to include 1,257,487 samples with 4,175,878 gene mutations curated from 23,870 publications, including 29,112 whole genomes (COSMIC, 2016). This database now also identifies cancer genes from DNA copy number, differential gene expression and differential DNA methylation.

1.1.5.1 The Cancer Genome Atlas Project

Based in the US, The Cancer Genome Atlas (TCGA) project was established in 2005, a combined effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) (TCGA, 2017). They first set out to demonstrate the pilot project on brain (McLendon *et al.*, 2008), ovarian (Bell *et al.*, 2011), and squamous cell lung (Hammerman *et al.*, 2012) cancers. In 2009, the project expanded aiming to analyse 500 samples each for 20-25 tumour tissue types. They have since exceeded that goal, with data available for 33 cancer types including 10 “rare” cancers, a total of over 10,000 samples.

The TCGA projects set out to generate a molecular “profile” of the tumour (and some matched normal tissue) samples: the genotype, somatic mutations, gene expression, DNA copy number, and RNA methylation levels. While these were originally performed largely with microarray technologies, exome and RNA-Seq has been since adopted and performed for many TCGA samples, with whole genomes being performed for some samples. Data which cannot be used to identify the patients (such as somatic mutation, expression, methylation, and various clinical factors) are publicly available.

1.1.5.1.1 Findings from Cancer Genomes

The Cancer Genome Atlas pilot projects (Bell *et al.*, 2011; Hammerman *et al.*, 2012; McLendon *et al.*, 2008) serve to demonstrate the power of applying genomics technologies to cancer research at such a scale. In addition to sequencing the whole genome or a subset (exome), DNA copy number, gene expression, DNA methylation, and somatic mutations were also analysed. The initial projects used microarray technologies for expression and methylation data but these have since been replaced by RNA-Seq for expression. TCGA demonstrated the potential discovery of the molecular basis of cancer by analysing 206 glioblastoma brain cancer samples (McLendon *et al.*, 2008), highlighting the roles of *ERBB2*, *NF1*, *TP53*, and *PIK3R1* mutations, along with altered methylation of *MGMT*, and the core pathways of RTK, p53, and RB signalling in brain cancer. An analysis of 489 serous ovarian cancers (Bell *et al.*, 2011) similarly reported *TP53* mutations specifically over-represented in high grade tumours and reported 133 copy number variants, 168 differentially methylated regions, and recurrently somatic mutations in 9 genes in low grade tumours including *NF1*, *BRCA1*, *BRCA2*, *RB1*, and *CDK12*. Four transcriptional subtypes of ovarian cancers were identified, alterations in *BRCA1*, *BRCA2*, and *CCLE* had an impact on patient survival, and the homologous recombination, NOTCH and FOXM1 signalling pathways were involved in ovarian cancer growth. The genomics of 178 squamous cell lung cancers (Hammerman *et al.*, 2012) were highly complex, averaging at 360 mutations in coding regions. While no targeted therapies existed for this cancer subtype, 11 recurrently mutated genes were identified including *TP53* and *HLA-A*. The pathways altered in various squamous cell lung cancers were NFE2L2, KEAP1, differentiation genes, PI3K, CDKN2A and RB1. These aberrant genes and pathways represent potential therapeutic targets which could be identified for most samples.

The TCGA breast cancer analysis (TCGA, 2012) consisted of 802 samples with exomes, copy number variants, RPPA protein quantification, and DNA methylation, mRNA, and microRNA arrays with 97 whole genomes sequenced. Four main molecular classes were identified to subtype the samples, despite considerable heterogeneity between samples. Recurrent mutations across more than 10% of samples were identified in *TP53*, *PIK3CA*, and *GATA*. TCGA further suggests subtypes by HER2 and EGFR protein levels. In a further analysis of 817 breast cancer samples including 127 invasive lobular breast and 88 mixed type samples (Ciriello *et al.*, 2015), 3 molecular subtypes of lobular breast cancer were identified. Lobular breast cancer was also characterised by recurrent mutations in *CDH1*, *PTEN*, *TBX2*, and *FOXA1*.

TCGA reported results of colon and rectal cancers in a combined analysis of 267 samples (Muzny *et al.*, 2012), finding no genomic distinction between colorectal cancers. Apart from 16% of hypermutated colorectal cancers, the remaining samples were very similar at the molecular level with 24 significantly recurrently mutated genes identified. These include the expected *APC*, *TP53*, *SMAD4*, *PIK3CA*, and *KRAS* genes. Additionally, novel recurrent mutations were identified in *ARID1A*, *SOX9*, and *FAM123* along with recurrent copy number alterations in *ERBB2* and *IFG2*. Thus the molecular findings of colon and rectal tumours can be applicable across colorectal cancers, including the known characteristics of microsatellite instability (MSI) and CpG island methylator phenotype (CIMP) found in some colorectal tumours.

The TCGA stomach cancer analysis of 295 samples (Bass *et al.*, 2014) identified 4 molecular subtypes of stomach cancers characterised by: the Epstein-Barr virus, MSI, genomics instability, and chromosomal instability. Aberrations in *PD-L1*, *PIK3CA*, and *JAK2* were also identified in stomach cancers which may present therapeutic targets.

1.1.5.1.2 Genomic Comparisons Across Cancer Tissues

TCGA have identified various genes as recurrent, driver mutations across cancer types which are likely to have a role in driving the proliferation of these cancers and present a molecular target that could be applied across tissue types. These include *TP53* (in brain, lung/head/neck squamous cell, breast, colorectal, uterine, and endometrial cancers), *ERBB2*/HER2/NEU (in brain, breast, colorectal, bladder, and lung cancers), *PIK3CA*, *PIK3R1* (in brain, breast, colorectal, endometrial, bladder, clear cell renal, and lung cancers), *BRCA1*/*BRCA2* (in breast and ovarian cancers), *NF1* (in brain, ovarian, and skin cancers), *ARID1A* (in colorectal, endometrial, and clear cell renal cancers), *KRAS* (in colorectal, endometrial, and skin cancers), *BRAF* (in colorectal, thyroid, and skin cancers), *EGFR* (in brain, breast, and lung cancers), and *PTEN* (in breast, endometrial, and uterine cancers) (Agrawal *et al.*, 2014; Akbani *et al.*, 2015; Bass *et al.*, 2014; Bell *et al.*, 2011; Burk *et al.*, 2017; Cherniack *et al.*, 2017; Ciriello *et al.*, 2015; Collisson *et al.*, 2014; Creighton *et al.*, 2013; Hammerman *et al.*, 2012; Kandoth *et al.*, 2013; Lawrence *et al.*, 2015; McLendon *et al.*, 2008; Muzny *et al.*, 2012; TCGA, 2012; Weinstein *et al.*, 2014). In addition to disregarding the tissue-based distinction between colon and rectal cancers based on molecular similarity (Muzny *et al.*, 2012), the TCGA project have observed differences within tumour types and proposed molecular subtyping for breast, clear cell renal, papillary renal, stomach,

skin, bladder, and prostate cancers (Abeshouse *et al.*, 2015; Akbani *et al.*, 2015; Bass *et al.*, 2014; Ciriello *et al.*, 2015; Creighton *et al.*, 2013; Hammerman *et al.*, 2012; Linehan *et al.*, 2016; Muzny *et al.*, 2012; TCGA, 2012; Weinstein *et al.*, 2014).

The “Pan cancer” project (Hoadley *et al.*, 2014; Weinstein *et al.*, 2013) analysed 3527 samples across 12 tissue types for DNA, RNA, protein, and epigenetic molecular profiles. This project was initiated in 2012 to perform a comprehensive analysis of molecular data across cancer types to identify molecular similarities and differences. Recurrent *TP53* mutations characterised high grade tumours across breast, ovarian, and endometrial cancers. HER2 was identified in brain, endometrial, bladder, and lung cancers, in addition to the known role of HER2 in breast cancers. *BRCA1* and *BRCA2* mutations were also detected across cancers, mainly breast and ovarian cancers as expected. Microsatellite instability characterised both endometrial and colorectal cancers. The Pan cancer project (Hoadley *et al.*, 2014) has identified 11 molecular subtypes across these tissues, 5 of corresponding to tissue cancer types and the remainder reassigned due to molecular similarities shared across cancer types. Squamous cell lung, head, and neck and a subset bladder cancers were grouped together by molecular similarities, characterised by a high frequency of *TP53* mutations. Conversely, bladder cancers were divided into 3 of these molecular subtypes with distinct profiles. This project further supports the genomic stratification of patients, demonstrated in breast cancer (Parker *et al.*, 2009; Pereira *et al.*, 2016; Perou *et al.*, 2000), which may apply to other cancer types and to molecular characteristics across them targeting recurrent mechanisms of cancer growth and progression (Hanahan and Weinberg, 2000, 2011).

1.1.5.1.3 Cancer Genomic Data Resources

While the findings from the TCGA projects themselves are a considerable contribution to understanding cancer biology within and across tissue types, the main eventual benefit of such projects will be the availability of the data for the research community to analyse further and use to inform future investigations (McLendon *et al.*, 2008; TCGA, 2017; Weinstein *et al.*, 2013). These serve as a vast resource of common and rare cancer types and are publicly available for further analysis (cBioPortal, 2017; TCGA, 2017; Zhang *et al.*, 2011). This also applies to the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) project which focuses on breast cancer which also aimed to identify novel molecular subtypes (Curtis *et al.*, 2012). They performed an analysis of 2433 breast cancer samples with long-term clinical data, gene expression, copy number variants, and 173 genes sequenced which identified 40 driver

mutations in breast cancer in addition to further support for molecular subtyping to identify patient groups with different clinical outcomes (Pereira *et al.*, 2016).

1.1.6 Genomic Cancer Medicine

There is much anticipation in cancer research for genomics technologies to have a clinical impact in cancer medicine: from diagnosis and prognosis to treatment developments and strategies. These may result either from direct use of genome or RNA-Seq in clinical laboratories or indirectly from biomarkers and treatments developed with research facilitated by genomics. This second strategy is likely to have a more immediate patient benefit due to the cost of genome sequencing, particularly considering adoption in public healthcare systems with a limited budget.

1.1.6.1 Cancer Genes and Driver Mutations

There are two main categories of “cancer genes” (Futreal *et al.*, 2001). Oncogenes are those activated in cancers either by gain of function mutations in proto-oncogenes, amplification of DNA copies, or elevated gene expression. Their normal functions are typically to regulate stem cells or to promote cellular growth and recurrent mutations are typically concentrated to particular gene regions. Conversely, tumour suppressor genes are those inactivated in cancer either by loss of function mutations, deletion of DNA copies, repression of gene expression, or hypermethylation. Their normal functions are typically to regulate cell division, DNA repair, and cell signalling.

Detecting these cancer genes is a major challenge in cancer biology and has been revolutionised by genomic technologies. Recurrent mutations, or DNA copy number variants and differential gene expression or DNA methylation are all indicative of cancer genes (Mattison *et al.*, 2009), which can be detected in genomics data (Pereira *et al.*, 2016; Weinstein *et al.*, 2013). Important “driver” cancer genes (Stratton *et al.*, 2009) are difficult to detect from “passenger” mutations due to patient variation, tumour heterogeneity, and genomic instability. However, many cancer genes have been replicated from previous studies or well supported from genomics data. There remains the challenge of translating the identification of cancer genes to patient benefit with characterisation of variants of unknown significance, which mutation or gene expression markers can be used to monitor tumour progression or treatment response, and design of therapeutic intervention against many molecular target for which they have yet to be developed or repurposed from other disease to cancers.

Driver mutations can be identified by whether they co-occur or are mutually exclusive with mutations in other genes in cancers, are recurrently mutated across a

significant proportion of samples for a specific tissue type, or if mutations are recurrent across different cancer tissue types (cBioPortal, 2017; Pereira *et al.*, 2016; COSMIC, 2016; Weinstein *et al.*, 2013; Zhang *et al.*, 2011). Approximately 140 driver mutations have been identified, including many novel genes in particular cancers from genomics studies, with 2–8 in typically occurring in each tumour usually affecting cell fate, survival, or genome maintenance (Vogelstein *et al.*, 2013).

1.1.6.2 Personalised or Precision Cancer Medicine

The notion of using a patient’s genome to tailor healthcare to an individual has been appealing since the advent of genomics, popularised with the term “personalised medicine”. This approach was expected to span from preventative lifestyle advice to effective treatments. Personalised medicine was described in contrast with current strategies of health advice, screening, prognostics, and treatments based on what works well for the majority of the population. Adverse effects of these treatments occur in a significant subpopulation, particularly demographics under-represented in clinical studies.

The importance of genomics is still recognised in translational cancer research. Applications are particularly emphasised in molecular diagnosis, prognosis, and treatments of patients already presenting with cancers in the clinic rather than preventative medicine. This is in part due to the vast number of variants of unknown clinical significance, the ethical issue of reporting on incidental findings, and the regulatory issues direct-to-consumer genetics companies have encountered offering health risk assessment.

More recently the term “genomic medicine” has been preferred to describe the paradigm of treating cancers by their genomic features, particularly grouping patients by the mutation, expression, or DNA methylation profiles of their cancers. Radical proponents advocate for these molecular subtypes to supercede tissue or cell type specific diagnosis of cancers. However, in practice they are often used in combination, with clinical and pathological factors being informative of prognosis and the medical expertise required for treatment. The related term of “precision medicine” also stems from this trend with the rationale to target these molecular subtypes with separate treatment strategies, particularly in developing and applying treatments targeted against a particular mutation specific to cancers. To this end much research in this field is focused on identifying mutations and gene expression signatures amenable to distinguishing cancers, particularly oncogenic driver mutations, and developing treatments against them.

1.1.6.2.1 Molecular Diagnostics and Pan-Cancer Medicine

There is growing support for the use of molecular tools such as mutations or gene expression signatures to diagnose tumour subtypes addition to (or in lieu of) tissue of origin or histology. This is particularly important in breast cancer where analysis of molecular data detected several distinct “intrinsic subtypes” with differences in malignancy and patient outcome which were distinguished by molecular mechanisms rather than tissue or cellular phenotype (Parker *et al.*, 2009; Perou *et al.*, 2000). Conversely, common molecular mechanisms may be shared between cancers across tissue types as discovered by the “Pan cancer” studies, such as those conducted by the TCGA and International Cancer Genome Consortium (ICGC) projects, which combined molecular profiles across tissue types Weinstein *et al.* (2013). The molecular subtypes could feasibly be included in clinical testing as a panel of biomarkers for diagnostics and prognosis. Such biomarkers also have the potential to monitor drug response or risk of recurrence. This also raises the need for development of treatments that target these molecular subtypes.

1.1.6.3 Targeted Therapeutics and Pharmacogenomics

Targeted therapies with specificity against a molecular target are emerging as precision cancer medicine. Molecular targets can be tested in laboratory conditions with RNA interference or pharmacological agents. Identification of molecular targets is important for developing novel anti-cancer treatments along with validation and drug testing. For oncogenic mutations, the recurrent mutant variant or overexpressed gene is directly inhibited using structure-aided drug design or compound screening. However, oncogenes with high homology to other genes or tumour suppressor genes (where lost in cancers) are not amenable to direct targeting (Kaelin, Jr, 2009).

Despite controversy over their prohibitively high cost (PHARMAC, 2016), targeted therapeutics have been applied as monoclonal antibodies against oncogenes (such as *HER2*) with relative success in clinical trials (Miles, 2001), generating considerable interest in wider application of this approach. Targeted therapeutics have potential to have applications across cancer tissue types, specificity against tumour cells, wide therapeutic windows, and combination therapies (even in advanced disease or as a chemopreventative in high-risk individuals).

1.1.6.3.1 Targeting Oncogenic Driver Mutations

Oncogene targeted therapies have also been developed with some examples of effective clinical application against cancers. However, they have already begun to manifest problems with resistance, recurrence, tissue specificity, and design of inhibitors specific to oncogenic variants rather than proto-oncogene precursors. Targeted anticancer therapeutics can exploit complex interactions to distinguish normal and cancerous cells which may benefit from studies of gene regulation or interaction networks. The unexpected synergy between inhibitors of the oncogenes $BRAF^{V600E}$ and $EGFR$ in colorectal cancer is an example of such a system Prahallad *et al.* (2012).

Despite successful application of vemurafenib against $BRAF^{V600E}$ in melanomas Diestmann and Tabernero (2011); Ravnan and Matalka (2012), colorectal cancers with $BRAF^{V600E}$ mutations have poor prognosis and lack drug response. Prahallad *et al.* (2012) used an RNA interference (RNAi) screen and found that $EGFR$ inhibition is synergistic with vemurafenib against $BRAF^{V600E}$ in colon cell lines and xenografts due to feedback activation of $EGFR$. Vemurafenib induced rapid reactivation of MAPK/ERK signalling via $EGFR$ in colorectal cell lines in a tissue-specific manner Corcoran *et al.* (2012) and may be relevant to acquired resistance in melanoma Sun *et al.* (2014). Thus combination therapies against several molecular pathways may be necessary to anticipate acquired resistance Ravnan and Matalka (2012) and targeted therapeutics may be further refined from understanding the pathway structure and functional interactions across cancer cells.

1.1.6.4 Systems and Network Biology

It is also important to consider that driver mutations in oncogenes and tumour suppressor genes do not occur in isolation. The genetic interaction, regulatory and cellular signalling, and metabolic reactions of are all inter-related and may each be perturbed by aberrations in gene function occurring in cancers. These relationships can be represented by biological networks by mapping pairs of genes with a particular relationship. Due to the complexity of a cell, these molecular networks are very large consisting of thousands of nodes comprised by genes or proteins.

The properties of large networks were first studied by constructing random networks by randomly linking a fixed number of nodes (Erdős and Rényi, 1959, 1960). Despite the random nature of these networks, properties such as their connectivity were well characterised. The vertex degree (number of partners for each node) of random network follows a Poisson distribution, however this property does not hold in nature, suggesting

that natural networks are non-random or not formed in this way Barabási and Oltvai (2004).

This work formed the foundation for studying complex networks (van Steen, 2010), which model features of real world networks not found in Erdős and Rényi’s random networks (Erdős and Rényi, 1959, 1960). The small world property, made popular by findings in social networks (Travers and Milgram, 1969), is the remarkably short path lengths between any nodes in a small world network. A small world network is well-connected with a characteristic path length (the average length of shortest paths between all pairs of nodes) proportional to the logarithm of the number of nodes. Watts and Strogatz (1998) developed a model of random rewiring of a regular network to construct random networks with the small world property and a high clustering coefficient. While these properties are more representative of networks occurring in nature, their model is limited by the degree distribution which converges to a Poisson distribution as it is rewired Barrat and Weigt (2000).

The vertex degree distribution of naturally occurring networks often follows a power law distribution with the majority of nodes having far fewer connections than average and a small subset of highly connected network ‘hubs’ Barabási and Albert (1999). Hubs further differentiate into ‘party’ hubs (which interact simultaneously with many partners) and ‘date’ hubs (which interact with different partners in different conditions) Han *et al.* (2004). Network hubs can also be classed as associative or dissociative depending on whether they tend toward or away from connecting directly to other network hubs (van Steen, 2010). The associative and dissociative properties can also be used to test whether nodes of a particular subgroup (e.g., gene function) associate with each other.

Barabási and Albert (1999) constructed a network model in an entirely different way to randomly generate scale-free networks which have a power law degree distribution. They constructed random networks by preferential attachment, modelling growth of a network by sequentially adding nodes with links to existing nodes. The scale-free nature of the random networks was ensured by adding new nodes with an increasing probability of attachment to an existing node if it has higher degree. These networks successfully capture the scale-free nature of many real world networks with short characteristic path length and low eccentricity resulting in super small worlds Barabási and Albert (1999). Scale-free networks are limited by a low clustering coefficient and lack of modular structure; however, they have enabled the study of scale-free network topology and

served as a basis for modified scale-free models (Dorogovtsev and Mendes, 2003; Holme and Kim, 2002).

Han *et al.* (2004) observed dynamic modularity in biological networks and suggested the network structure may underpin genetic robustness and plasticity. They focus on network hubs which are more likely to be essential genes and define the subgroups of hubs based on correlation of gene expression with protein-protein interaction partners: ‘party’ hubs (which interact simultaneously with many partners) and ‘date’ hubs (which interact with different partners in different conditions). Party and date hubs occurred most frequently within and between network modules respectively. Party hubs were considered local regulators, whereas date hubs were considered important to network connectivity as global regulators. This distinction between classes of network hubs was supported by differences in tissue specificity and clinical relevance as a proposed predictor of clinical outcome in breast cancer with an area under the receiver operating characteristic (AUROC) of 0.784 Taylor *et al.* (2009). However, correlation between expression and protein interactions were not robustly reproduced. The importance of date hubs has been criticised for assuming a bimodal distribution and basing the global importance of data hubs on a small subset Agarwal *et al.* (2010). As an alternative interpretation, (Agarwal *et al.*, 2010) suggest the importance of interactions rather than network hubs as interactions important to the network were between functionally similar proteins. Network hubs can also be classed as associative or dissociative depending on whether they tend toward or away from connecting directly to other network hubs (van Steen 2010). The associative and dissociative properties can also be used to test whether nodes of a particular subgroup (e.g., gene function) associate with each other.

Applications of network theory are diverse, including uses in social sciences, engineering, and computer science. Due to their complexity and difficulty of gathering sufficient empirical data, biological applications of network theory are relatively unexplored. High-throughput technologies such as siRNA screens, two-hybrid screens, microarrays and massively parallel sequencing have made generating genome-scale molecular data feasible and enabled analysis of biological networks at the molecular level. Many types of inter-related molecular networks can be constructed and analysed, depending on the biological application. Genetic interaction networks will be the focus of this project because they are relatively unexplored compared to other molecular networks, have potential for applications in drug discovery (particularly cancer treatment), and may lead to better understanding of the role of genetics in cellular function and disease. Genetic interactions are usually studied at a high-throughput scale in simple model or-

ganisms such as bacteria, yeasts or the nematode worm; studies in humans, mammals, and non-model organisms (where applications would have the most societal impact) are limited by cost, time and labour constraints. Computational approaches with effective predictive models are the only feasible approach to study the connectivity of a biological network in a complex metazoan cell at the genome-scale.

1.1.6.4.1 Network Medicine, and Polypharmacology

Molecular networks are biological networks consisting of biological molecules including genes, transcripts (with non-coding and microRNAs), or proteins related by known interactions and gene regulatory or metabolic pathways. Targeted therapeutics have had some success for drug discovery, particularly in anticancer applications, including exploiting these molecular networks by designing combination therapies and applying a network pharmacology framework Hopkins (2008). Rational design of drugs selective to a single target has often failed to deliver clinical efficacy. Many existing effective drugs modulate multiple proteins, having been selected for biological effects or clinical outcome rather than molecular targets. Proponents of network biology and polypharmacology (specific binding to multiple targets) recommend developing drugs with a desired target profile designed for the target topology Barabási and Oltvai (2004); Hopkins (2008). Multi-target treatments aim to achieve a clinical outcome through modulation of molecular networks since the genetic robustness of a cell often compensates for loss of a single molecular target.

While multi-target drugs may be more difficult to design, they are faster to test clinically than drug combinations which are usually required to be tested separately first Hopkins (2008). Synthetic lethal treatments for cancer, drug combinations and multi-target drugs to combat resistance to chemotherapy and antibiotics can be informed by biological networks Barabási and Oltvai (2004); Hopkins (2008). Further optimisation of timing and dosing of drug combinations may increase efficacy of treatments with low efficacy applied separately. Low doses and drug holidays are other counter intuitive approaches which may increase clinical efficacy, reduce adverse effects, and reduce drug resistance (Sun *et al.*, 2014; Tsai *et al.*, 2012).

A molecular map of the interactions and pathways in the mammalian cellular network has the potential to impact upon drug design and clinical practice, particularly in treatment of cancer and infectious disease. Characterisation of the target system and impact of existing treatments, such as *BRAF*^{V600E} and *EGFR* inhibitors, enable wider application of the mechanisms for such interventions exploiting genetic interactions or

pathways. This could lead to development of more effective treatment interventions for these systems and prediction of similar molecular systems for development of novel drug targets and combinations.

1.2 A Synthetic Lethal Approach to Cancer Medicine

Synthetic lethality has vast potential to improve cancer medicine by expanding application of targeted therapeutics to include inactivation of tumour suppressors and genes that are difficult to target directly. Synthetic lethal interactions are also studied for gene function and drug mode-of-action in model organisms. This section introduces the concept of synthetic lethality as it was originally conceived and how it has been adopted conceptually in cancer research. Detecting these interactions at scale and interpreting them is the focus of this thesis, hence we start with an overview of the concepts involved, initial work on the interaction, and the rationale for applications to cancer. Specific investigations into synthetic lethality in cancer, detection by experimental screening, and prediction by computational analysis will then be reviewed.

1.2.1 Synthetic Lethal Genetic Interactions

Genetic interactions are a core concept of molecular biology, discovered among earliest investigations of Mendelian genetics, and receiving revived interest with new technologies and potential applications. Biological epistasis is the effect of an allele at one locus “masking” the phenotype of another locus (Bateson and Mendel, 1909). Statistical epistasis is where there is significant disparity between the observed and expected phenotype of a double mutant, compared to the respective phenotypes of single mutants and the wild-type (Fisher, 1919). Fisher’s definition lends itself to quantitative traits and more broadly encompasses synthetic genetic interactions (synthetic genetic interactions). These have become popular for studies in yeast genetics and cancer drug design (Boone *et al.*, 2007; Kaelin, Jr, 2005).

Synthetic genetic interactions are substantial deviations of growth or viability from the expected null mutant phenotype (of an organism or cell) assuming additive (deleterious) effects of the single mutants. The double mutant does not necessarily have either single mutant phenotype (as shown for cellular growth phenotypes in Figure 1.1). Most SGIs are more viable than either single mutant or less viable than the expected double mutant. Mutations are “synergistic” in negative SGIs with more deviation from the wild-type than expected. Formally, “synthetic sick” (SSL) and “synthetic lethal” (SL) interactions are negative SGIs giving growth inhibition and inviability respectively.

Synthetic lethality in cancer research more broadly describes any negative SGI with specific inhibition of a mutant cell, including SSL interactions. Mutations are “alleviating” in positive SGIs with less deviation from the wild-type than expected. For viability, “suppression” and “rescue” are positive SGIs giving at least partial restoration of wild-type growth from single mutants with growth impairment and lethal phenotypes respectively. Negative SGIs were markedly more common than positive SGIs in a number of studies in model systems Boucher and Jenna (2013); Tong *et al.* (2004).




Figure 1.1: **Synthetic genetic interactions.** Impact of various negative and positive SGIs: negative interactions involve deleterious (sick) or inviable (lethal) phenotypes whereas positive interactions involve restoring viability by masking or suppressing the other mutation or complete rescue of the wildtype phenotype. Figure adapted from (Costanzo *et al.*, 2011) concerning growth viability fitness in yeast.

1.2.2 Synthetic Lethal Concepts in Genetics

Synthetic lethal genes are generally regarded to arise due to functional redundancy. Due to the functional level of SGIs, synthetic lethal genes do not need directly interact, nor be expressed in the same cell or at the same developmental stage: serving related functions is sufficient to affect cell (or organism) viability and be relevant to drug-mode-of-action cancer biology. Combined loss of genes performing an essential or important function in a cell are therefore deleterious. Synthetic lethal gene pairs are therefore pairwise essential with “induced essentiality”: each synthetic lethal gene becomes essential to the cell upon loss of the other.

Since synthetic lethal gene partners can be affected by extracellular stimuli such as chemicals, essentiality of synthetic lethal genes can be induced by the environment of a cell. An environmental stress condition may inhibit one or the other synthetic lethal gene, such as exposure to chemicals, in which case the synthetic lethal partner gene is

“conditionally essential” (Hillenmeyer, 2008). Thus the evolutionary rationale for the abundance of SGIs (compared to the surprisingly low number of essential genes) in a Eukaryotic genome attributed to genetic functional redundancy and network robustness of a cell which are advantageous to survival.

Biological functions are typically performed by a pathway of genes (or their products). Many genes of the same pathway may be functionally interchangeable as synthetic lethal partners of a particular gene since loss of the pathway is deleterious without the synthetic lethal partner gene. Therefore biological pathways can be subject to induced essentiality under loss of a gene and synthetic lethality may occur at pathway level or in a gene regulation network.

1.2.3 Studies of Synthetic Lethality

Genetic high-throughput screens have identified unexpected, functionally informative, and clinically relevant synthetic lethal interactions; including synthetic lethal partners of genes recurrently mutated in cancer or attributed to familial early-onset cancers. While screening presents an appealing strategy for synthetic lethal discovery, computational approaches are becoming popular as an alternative or complement to experimental methods to overcome inherent bias and limitations of experimental screens. An array of recently developed computational methods (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015; Tiong *et al.*, 2014; Wang and Simon, 2013; Wappett, 2014) show the need for synthetic lethal discovery in the fundamental genetics and translational cancer research community. However, existing computational methods are not suitable for queries of genomic data for interacting partners of a particular gene: they have been applied pairwise across the genome, do not have software released to apply the methodology, or lack statistical measures of error for further analysis. A robust prediction of gene interactions is an effective and practical approach at a scale of the entire genome for ideal translational applications, analysis of biological systems, and constructing functional gene networks.

1.2.3.1 Synthetic Lethal Pathways and Networks

SGIs are very common in genomes, with $4\times$ more interactions detected with synthetic gene array mating screens than protein-protein interactions yeast-2-hybrid studies (Tong *et al.*, 2004). The SGI network is scale-free with power-law vertex degree distribution and low average shortest path length (3.3) as expected for a complex biological network (Barabási and Oltvai, 2004). Highly connected “hub” genes with the highest number of links (vertex degree) are functionally important with many negative

SGI hubs involved in cell cycle regulation and many positive SGI hubs involved in translation (Baryshnikova *et al.*, 2010b; Costanzo *et al.*, 2010). Negative SGIs were far more common than positive SGIs, with synthetic gene loss being more likely to be deleterious to cell than advantageous which indicates that synthetic lethality may be comparably easier to detect than other SGIs.

Essential pathways are highly buffered with $5\times$ more interactions than other SGIs, consistent with strong selection for survival, as found with conditional and partial mutations in essential genes (Davierwala *et al.*, 2005). This SGI network had scale-free topology and rarely shared interactions with the protein-protein interaction network. These networks are related by an “orthogonal” relationship: shared partners in one network tend to be themselves connected directly in the other network. Essential genes were likely to have closely related functions, whereas non-essential networks were relatively more inclined to have SGIs between distinct biological pathways.

1.2.3.1.1 Evolution of Synthetic Lethality

There is poor conservation of specific SGIs between *S. cerevisiae* and *S. pombe* with 29% of the interactions tested in both distantly related species being conserved between them (Dixon *et al.*, 2008). The remaining interactions show high species-specific differences; however, many of the species-specific interactions were still conserved between biological pathways, protein complexes, or protein-protein interaction modules. Similarly, conservation of pathway redundancy was also found between Eukaryotes (*S. cerevisiae*) and prokaryotes (*E. coli*) (Butland *et al.*, 2008). Negative SGIs were more likely to be conserved between biological pathways, whereas positive SGIs were more likely to be conserved within a pathway or protein complex (Roguev *et al.*, 2008).

A modest 5% of interactions were conserved between unicellular (*S. cerevisiae*) and multicellular (*C. elegans*) organisms. However, the nematode SGI network had similar scale-free topology and modularity despite differences in methodology: metazoan RNAi screens are incomplete knockouts whereas screening null mutations is feasible in yeast (Bussey *et al.*, 2006). The nematode SGI screen identified network hubs with important interactions to orthologues of known human disease genes (Lehner *et al.*, 2006). Despite the lack of direct conservation of SGIs between yeasts and nematode worms, genetic redundancy at the gene or pathway level may yet be consistent with an induced essentiality model of SGIs where gene functions are conserved with network restructuring over evolutionary change (Tischler *et al.*, 2008). While nematode models are more closely related to human cells, cancer cells can present growth and viability

phenotypes more comparable to yeast models. Therefore findings from both SGA and RNAi models are relevant to understanding cellular network structure and in healthy and cancerous human cells. RNAi has also been applied to human and mouse cancer cells in cell culture and genetic screening experiments. These findings suggest that SGI network “rewiring” is a concern for identifying specific synthetic lethal interactions in cancer and a pathway approach may be more robust in the context of evolution, patient variation, tumour heterogeneity, and disease progression.

1.2.4 Synthetic Lethal Concepts in Cancer

Loss of function occurs in many genes in cancers including tumour suppressors and yet few interventions target such mutations compared to targeted therapies for gain of function mutation in oncogenes (Kaelin, Jr, 2005). Synthetic lethality is a powerful design strategy for therapies selective against loss of gene function with potential for application against a range of genes and diseases (Fece de la Cruz *et al.*, 2015; Kaelin, Jr, 2009). Since synthetic lethality affects cellular viability by indirect functional relationships between genes, it is suitable for indirectly targeting mutations in cancers. Once synthetic lethal partners of cancer genes are identified, targeted therapeutics can be applied against them. When genes are disrupted in cancers, the induced essentiality of synthetic lethal partners is a vulnerability that may be exploited for anti-cancer therapy. This has the potential to be very specific against cancer cells (with the target mutation) over non-cancer cells (with a functional compensating gene). Analogous to “oncogene addiction”, where cancer cells adapt to particular oncogenic growth signals and become reliant on them to remain viable (Luo *et al.*, 2009; Weinstein, 2000), synthetic lethal partners of inactivated tumour suppressors are required to maintain cancer cell viability and proliferation. As such cancers are subject to “non-oncogene addiction” and are feasible anti-cancer drug targets.

The synthetic lethal approach to cancer medicine is most amenable to loss of function mutations in tumour suppressor genes, where it would feasibly be effective against any loss of function mutation across the tumour suppressor with a viable synthetic lethal partner gene (as shown in Figure 1.2). However, the approach may also be suitable for cases where cancer cells have mutations where the normal function of the gene is disrupted such as if it were overexpression (“synthetic dosage lethality”) or if an oncogene interfered with the function of the proto-oncogenic variant such as competitive inhibition. Thus synthetic lethality expands the range of cancer-specific mutations feasible to target with targeted therapeutics to absence of tumour suppressor genes and




Figure 1.2: **Synthetic lethality in cancer.** Rationale of exploiting synthetic lethality for specificity against a tumour suppressor gene (e.g., *CDH1*) while other cells are spared under the inhibition of a partner gene.

distinguishing highly homologous oncogenes by functional differences by targeting their synthetic lethal partners.

1.2.5 Clinical Impact of Synthetic Lethality in Cancer

The synthetic lethal interaction of *BRCA1* or *BRCA2* with *PARP1* in breast cancer is an example of how gene interactions are important in cancer, including translation to the clinic. These genetic interactions enable specific targeting of mutations in *BRCA1* or *BRCA2* tumour suppressor genes with PARP inhibitors by inducing synthetic lethality in breast cancer (Farmer *et al.*, 2005). PARP inhibitors are one of the first targeted therapeutics against a tumour suppressor mutation with success in clinical trials.

BRCA1 or *BRCA2* and *PARP1* genes demonstrate the application of the synthetic lethal approach to cancer therapy Ashworth (2008); Kaelin, Jr (2005). *BRCA1* and *BRCA2* are homologous DNA repair genes, widely known as tumour suppressors; mutation carriers have substantially increased risk of breast (risk by age 70 of 57% for *BRCA1* and 59% for *BRCA2*) and ovarian cancers (risk by age 70 of 40% for *BRCA1* and 18% for *BRCA2*) (Chen and Parmigiani, 2007). The *BRCA1* or *BRCA2* genes, which usually repair DNA or destroy the cell if it cannot be repaired, have inactivating somatic mutations in some familial and sporadic cancers. Poly-ADP-ribose polymerase

(PARP) genes are tumour suppressor genes involved in base excision DNA repair. Loss of PARP activity results in single-stranded DNA breaks. However, *PARP1*^{-/-} knock-out mice are viable and healthy indicating low toxicity from PARP inhibition (Bryant *et al.*, 2005).

Bryant *et al.* (2005) showed that *BRCA2* cells were sensitive to PARP inhibition by siRNA of *PARP1* or drug inhibition (which targets *PARP1* and *PARP2*) using Chinese hamster ovary cells, MCF7 and MDA-MB-231 breast cell lines. This effect was sufficient to kill mouse tumour xenografts and showed high specificity to *BRCA2* deficient cells in culture and xenografts. Farmer *et al.* (2005) replicated these results in embryonic stem cells and showed that *BRCA1* cells were also sensitive to PARP inhibition relative to the wild-type with siRNA and drug experiments in cell culture and drug activity against *BRCA1* or *BRCA2* deficient embryonic stem cell mouse xenografts. They found evidence that PARP inhibition causes DNA lesions, usually repaired in wild-type cells, which lead to chromosomal instability, cell cycle arrest, and induction of apoptosis in *BRCA1* or *BRCA2* deficient cells. Therefore, the pathways cooperate to repair DNA giving a plausible mechanism for combined loss as an effective anti-cancer treatment.

Thus PARP inhibitors have potential for clinical use against *BRCA1* or *BRCA2* mutations in hereditary and sporadic cancers (Ashworth 2008; Kaelin2005). PARP inhibition has been found to be effective in cancer patients carrying *BRCA1* or *BRCA2* mutations and some other ovarian cancers, suggesting synthetic lethality between PARP and other DNA repair pathways (Ström and Helleday, 2012). This supports the potential for PARP inhibition as a chemo-preventative alternative to prophylactic surgery for high risk individuals with *BRCA1* or *BRCA2* mutations (Ström and Helleday, 2012). Hormone-based therapy has also been suggested as a chemo-preventative in such high risk individuals and aromatase inhibitors have completed phase I clinical trials for this purpose (Bozovic-Spasojevic2012). Ström and Helleday (2012) also postulate increased efficacy of PARP inhibitors in the hypoxic DNA-damaging tumour micro-environment.

A PARP inhibitor, olaparib, showed fewer adverse effects than cytotoxic chemotherapy and anti-tumour activity in phase I trials against *BRCA1* or *BRCA2* deficient familial breast, ovarian, and prostate cancers (Fong *et al.*, 2009) and sporadic ovarian cancer (Fong *et al.*, 2010). AstraZeneca has reported phase II trials showing the treatment is effective in *BRCA1* or *BRCA2* deficient breast (Tutt *et al.*, 2010) and ovarian cancers (Audeh *et al.*, 2010) with a favourable therapeutic window and similar toxicity between carriers of *BRCA1* or *BRCA2* mutations and sporadic cases. As-

traZeneca announced that olaparib has begun phase III trials for breast and ovarian cancers in 2013. Mixed results in phase II trials in ovarian cancer are behind the delays addressed by retrospective analysis of the cohort subgroup with confirmed mutation of *BRCA1* or *BRCA2* genes in the tumour; unsurprisingly these patients, benefit most from the PARP inhibitor treatment and have increased platinum sensitivity in combination treatment. These PARP inhibitors are FDA approved for some cancers McLachlan *et al.* (2016), are effective against germline and sporadic *BRCA1* or *BRCA2* mutations, and are a potential prevention alternative to prophylactic surgery for high risk mutation carriers Ström and Helleday (2012).

This demonstrates the clinical impact of a well characterised system of synthetic lethality with known cancer risk genes. Synthetic lethality has the benefit of being effective against inactivation of tumour suppressor genes by any means, broader than targeting a particular oncogenic mutation (Kaelin, Jr, 2005). The targeted therapy is effective in both sporadic and hereditary *BRCA1* or *BRCA2* deficient tumours acting against an oncogenic molecular aberration across several tissues.

1.2.6 High-throughput Screening for Synthetic Lethality

The function of signalling pathways and combinations of interacting genes are important in cancer research but classical genetics approaches have been limited to non-redundant pathways (Fraser, 2004). The emerging RNAi technologies have vastly expanded the potential for studying genetic redundancy in mammalian experimental models including testing experimentally for synthetic lethality (Fraser, 2004). Identifying synthetic lethality is crucial to study gene function, drug mechanisms, and design novel therapies (Lum *et al.*, 2004). Candidate selection of synthetic lethal gene pairs relevant to cancer has shown some success but is limited because interactions are difficult to predict; they can occur between seemingly unrelated pathways in model organisms (Costanzo *et al.*, 2011). While biologically informed hypotheses have had some success in synthetic lethal discovery (Bitler *et al.*, 2015; Bryant *et al.*, 2005; Farmer *et al.*, 2005), interactions occurring indirectly between distinct pathways would be missed (Boone *et al.*, 2007; Costanzo *et al.*, 2011). Scanning the entire genome for interactions against a clinically relevant gene is an emerging strategy being explored with high-throughput screens (Fece de la Cruz *et al.*, 2015) and computational approaches (Boucher and Jenna, 2013; van Steen, 2012).

Experimental screening for synthetic lethality is an appealing strategy for wider discovery of functional interactions *in vivo* despite many potential sources of error which

must be considered. The synthetic lethal concept has both genetic and pharmacological screening applications to cancer research. Genetic screens, with RNAi to discover the specific genes involved, inform development of targeted therapies with a known mode of action, anticipated mechanisms of resistance, and biomarkers for treatment response. RNAi is a transient knockdown of gene expression more similar to the effect of drugs than complete gene loss and makes comparison to screens in model organisms difficult (Bussey *et al.*, 2006). The RNAi gene knockdown process has inherent toxicity to some cells, potential off-target effects, and issues with a high false positive rate. Therefore, it is important to validate any candidates in a secondary screen and replicate knockdown experiments with a number of independent shRNAs. Alternative gene knockout procedures have also been proposed for synthetic lethal screening including a genome-wide application of the CRISPR/Cas9/sgRNA genome editing technology (Sander and Joung, 2014), episomal gene transfer (Vargas *et al.*, 2004), or RNAi with lentiviral transfection for delivery of shRNA (Telford *et al.*, 2015). Genetic screens have potential for quantitative gene disruption experiments to selectively target overexpressed genes in cancer via synthetic dosage lethality. While powerful for understanding fundamental cellular function, analysis of isogenic cell lines is inherently limited by assuming only a single mutation differs between them despite susceptibility to “genetic drift” and cannot account for diverse genetic backgrounds or tumour heterogeneity (Fece de la Cruz *et al.*, 2015). Genetic screens thus identify targets to develop or repurpose targeted therapies for disease but alone will not directly identify a lead compound to develop for the market or clinical translation.

Chemical screens are immediately applicable to the clinic by directly screening for selective lead compounds with suitable pharmacological properties. However chemical screens lack a known mode of action, may affect many targets, and screen a narrow range of genes with existing drugs. With either approach there are many challenges translating candidates into the clinic such as finding targets relevant to a range of patients, validation of targets, accounting for a range of genetic (and epigenetic) contexts or tumour micro-environment, identifying effective synergistic combinations, enhancers of existing radiation or cytotoxic treatments, avoiding inherent or acquired drug resistance, and developing biomarkers for patients which will respond to synthetic lethal treatment, including integrating these into clinical trials and clinical practice. Identifying specific target genes is an effective way to anticipate such challenges, which can be approached with genetic screens, so we will focus on these and computational alternatives. Screening methods have proven a fruitful area of research, despite being

costly, laborious, and having many different sources of error. These limitations suggest a need for complementary computational approaches to synthetic lethal discovery.

1.2.6.1 Synthetic Lethal Screens

Overexpression of genes is another suitable application for synthetic lethality since overexpressed genes cannot be distinguished from the wild-type by direct sequence specific targeted therapy. Overexpression of oncogenes, such as *EGFR*, *MYC*, and *PIM1*, has been found to drive many cancers. *PIM1* is a candidate for synthetic lethal drug design in lymphomas and prostate cancers, where it interacts with *MYC* to drive cancer growth. van der Meer *et al.* (2014) performed an RNAi screen for synthetic lethality between *PIM1* overexpression and gene knockdown in RWPE prostate cancer cell lines. *PLK1* gene knockdown and drug inhibition was effective as a specific inhibitor of *PIM1* overexpressing prostate cells in cell culture and mouse tumour xenografts. *PLK1* inhibition reduced *MYC* expression in pre-clinical models, consistent with expression in human tumours in which *PIM1* and *PLK1* are co-expressed and correlated with tumour grade. Thus RNAi screening was valuable to identify therapeutic targets and biomarkers for patient response as demonstrated with the finding of *PLK1* as a candidate drug target against prostate cancer progression.

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a cancer syndrome of predisposition to benign tumours in the uterus and risk of malignant cancer of the kidney attributed to inherited mutations in fumarate hydratase (*FH*). Boettcher *et al.* (2014) performed an RNAi screen on HEK293T renal cells for synthetic lethality with *FH*. They found enrichment of haem metabolism (consistent with the literature) and adenylate cyclase pathways (consistent with cAMP dysregulation in *FH* mutant cells). Synthetic lethality between *FH* mutation and adenylate cyclases was validated with gene knockdown, drug experiments, and replicated across both HEK293T renal cells and VOK262 cells derived from a HLRCC patient, suggesting new potential treatments against the disease.

Similarly, hereditary diffuse gastric cancer (HDGC) is a cancer syndrome of predisposition to early-onset malignant stomach and breast cancers attributed to mutations in E-cadherin (*CDH1*). Telford *et al.* (2015) performed an RNAi screen on MCF10A breast cells for synthetic lethality with *CDH1*. They found enrichment of G-protein coupled receptors (GPCRs) and cytoskeletal gene functions. The results were consistent with a concurrent drug compound screen with a number of candidates validated by lentiviral shRNA gene knockdown and drug testing including inhibitors of Janus kinase, histone deacetylases, phosphoinositide 3-kinase, aurora kinase, and tyrosine ki-

nases. Therefore the synthetic lethal strategy has potential for clinical impact against HDGC, with particular interest in interventions with low adverse effects for chemoprevention, including repurposing existing approved drugs for activity against *CDH1* deficient cancers.

RNAi screening for synthetic lethality is also useful for functional genetics to understand drug sensitivity. Aarts *et al.* (2015) screened WiDr colorectal cells for synthetic lethality between *WEE1* inhibitor treatment and an RNAi library of 1206 genes with functions known to be amenable to drug treatment or important in cancer such as kinases, phosphatases, tumour suppressors, and DNA repair (a pathway *WEE1* regulates). Screening identified a number of synthetic lethal candidates including genes involved in cell cycle regulation, DNA replication, repair, homologous recombination, and Fanconi anaemia. Synthetic lethality with cell-cycle and DNA repair genes was consistent with the literature and validation in a panel of breast and colorectal cell lines supported checkpoint kinases, Fanconi anaemia, and homologous recombination as synthetic lethal partners of *WEE1*. These results show that synthetic lethality can be used to improve drug sensitivity as a combination treatment, especially to exploit genomic instability and DNA repair, which are known to be clinically applicable from previous results with *BRCA1* or *BRCA2* genes and PARP inhibitors (Lord *et al.*, 2015). Therefore, *WEE1* inhibitors are an example of treatment which could be repurposed with the synthetic lethal strategy. Similar findings would be valuable to clinicians as a source of biomarkers and novel treatments. While using a panel of cell lines to replicate findings across genetic background is a promising approach to ensure wide clinical application of validated synthetic lethal partners, a computational approach may be more effective as it could account for wider patient variation than scaling up intensive experiments on a wide array of cell lines and could screen beyond limited candidates from an RNAi library.

Chemical genetic screens are also a viable strategy to identify therapeutically relevant synthetic lethal interactions. Bitler *et al.* (2015) investigated *ARID1A* mutations, aberrations in chromatin remodelling known to be common in ovarian cancers, for drug response. Ovarian RMG1 cells were screened for drug response specific to *ARID1A* knockdown cells. They used *ARID1A* gene knockdown for consistent genetic background, with control experiments and 3D cell culture to ensure relevance to drug activity in the tumour micro-environment. Screening a panel of commercially available drugs targeting epigenetic regulators found *ESH2* methyltransferase inhibitors effective and specific against *ARID1A* mutation with validation in a panel of ovarian cell

lines. Synthetic lethality between *ARID1A* and *ESH2* was supported by decreases in H3K27me3 epigenetic marks and markers of apoptosis in response to *ESH2* inhibitors. This was mechanistically supported with differential expression of *PIK3IP1* and association of both synthetic lethal genes with the *PIK3IP1* promoter identifying the PI3K-AKT signalling pathway as disrupted when both genes were inhibited.

This successfully demonstrates the importance of synthetic lethality in epigenetic regulators, identifies a therapeutically relevant synthetic lethal interaction, and shows that chemical genetic screens could model drug response and combination therapy in cancer cells. However this approach is limited to finding synthetic lethal interactions between genes with known similar function, which may not be the most suitable for treatment. Further limiting experiments to genes with existing targeted drugs reduces the number of synthetic lethal interactions detected, assumes the specificity of drugs to a particular target, and many of these drugs are not yet clinically available yet anyway, although they are clinical trials for other diseases or limited to access by patients from a particular countries.

The examples above show that high-throughput screens are an effective approach to discover synthetic lethality in cancer with a wide range of applications. Screens are more comprehensive than hypothesis-driven candidate gene approaches and successfully find known and novel synthetic lethal interactions with potential for rapid clinical application. They have the power to test mode of action of drugs, find unexpected synthetic lethal interactions between pathways, or identify effective treatment strategies without needing a clear mechanism. However, synthetic lethal screens are costly, labour-intensive, error-prone, and biased towards genes with effective RNAi knockdown libraries. Limited genetic background, lethality to wild-type cell during gene knock-down, off-target effects, and difficulty replicating synthetic lethality across different cell lines, tissues, laboratories, or conditions stems from a high false positive rate and a lack of standardised thresholds to identify synthetic lethality in a high-throughput screen. Therefore there is a need for replication, validation, and alternative approaches to identify synthetic lethal candidates. Varied conditions between experimental screens and differences between RNAi and drug screens renders meta-analysis ineffective.

Genome-scale synthetic lethal experiments (across gene pairs) are not feasible, even in model organisms, and they typically focus on specific gene candidates or the partners of a gene of interest (such as importance in health). Therefore a computational approach is more suitable for this task and may further augment experimental screening to replicate screen candidates beyond experimental models.

1.2.7 Computational Prediction of Synthetic Lethality

1.2.7.1 Bioinformatics Approaches to Genetic Interactions

Prediction of gene interaction networks is a feasible alternative to high-throughput screening with biological importance and clinical relevance. There are many existing methods to predict gene networks, as reviewed by van Steen (2012) and Boucher and Jenna (2013) and summarised in Table 1.1. However, many of these methods have limitations including the requirement for existing SGI data, several data inputs, and reliability of gene function annotation. Many of the existing methods also assume conservation of individual interactions between species, which has been found not to hold in yeast studies (Dixon *et al.*, 2008). Tissue specificity is important in gene regulation and gene expression, which are used as predictors of genetic interaction. However, tissue specificity of genetic interactions cannot be explored in yeast studies and has not been considered in many studies of multicellular model organisms, human networks, or cancers. Similarly, investigation into tissue specificity of protein-protein interactions (PPIs), an important predictor of genetic interactions, is difficult given that high-throughput two-hybrid screens occur out of cellular context for multicellular organisms.

Table 1.1: Methods for Predicting Genetic Interactions

Method	Input Data	Species	Source	Tool Offered
Between Pathways Model	PPI, SGI	<i>S. cerevisiae</i>	Kelley and Ideker (2005)	
Within Pathways Model	PPI, SGI	<i>S. cerevisiae</i>	Kelley and Ideker (2005)	
Decision Tree	PPI, expression, phenotype	<i>S. cerevisiae</i>	Wong <i>et al.</i> (2004)	2 Hop
Logistic Regression	SGI, PPI, co-expression, phenotype	<i>C. elegans</i>	Zhong and Sternberg (2006)	Gene Orienteer
Network Sampling	SGI, PPI, GO	<i>S. cerevisiae</i>	Le Meur and Gentleman (2008) Le Meur <i>et al.</i> (2014)	SLGI(R)
Random Walk	GO, PPI, expression	<i>S. cerevisiae</i> <i>C. elegans</i>	Chipman and Singh (2009)	
Shared Function	Co-expression, PPI, text mining, phylogeny	<i>C. elegans</i>	Lee <i>et al.</i> (2010b)	WormNet
Logistic Regression	Co-expression, PPI, phenotype	<i>C. elegans</i>	Lee <i>et al.</i> (2010a)	GI Finder
Jaccard Index	GO, SGI, PPI, phenotype	Eukarya	Hoehndorf <i>et al.</i> (2013)	
Machine Learning			Pandey <i>et al.</i> (2010)	MNMC
Machine Learning Meta-Analysis			Wu <i>et al.</i> (2014)	MetaSL
Flux Variability Analysis		<i>E. coli</i>		
Flux Balance Analysis	Metabolism	<i>M. pneumoniae</i>	Güell <i>et al.</i> (2014)	
Network Simulation				

There are a number of existing computational methods for predicting synthetic lethal gene pairs in humans with a specific interest in cancer (as summarised in 1.2). While these demonstrate the power and need for predictions of synthetic lethality in human and cancer contexts, limitations of previous methods could be met with a

Table 1.2: Methods for Predicting Synthetic Lethality in Cancer

Method	Input Data	Source	Tool Offered
Network Centrality	protein-protein interactions	Kranthi <i>et al.</i> (2013)	
Differential Expression	Expression Mutation	Wang and Simon (2013)	
Comparative Genomics	Yeast synthetic gene interactions	Heiskanen and Aittokallio (2012)	
Chemical-Genomics	Homology		
Comparative Genomics	Yeast synthetic gene interactions Homology	Deshpande <i>et al.</i> (2013)	
Machine Learning		Discussed by Babyak (2004) and Lee and Marcotte (2009)	
Differential Expression	Expression	Tiong <i>et al.</i> (2014)	
Literature Database		Li <i>et al.</i> (2014)	Syn-Lethality
Meta-Analysis	Meta-Analysis Machine Learning	Wu <i>et al.</i> (2014)	MetaSL
Pathway Analysis		Zhang <i>et al.</i> (2015)	
Protein Domains	Homology	Kozlov <i>et al.</i> (2015)	
Data-Mining	Expression	Jerby-Arnon <i>et al.</i> (2014)	
Machine Learning	Somatic mutation and DNA CNV siRNA in cell lines	Ryan <i>et al.</i> (2014) Crunkhorn (2014) Lokody (2014)	DAISY (method)
Genome Evolution	Expression	Lu <i>et al.</i> (2013)	
Hypothesis Test	DNA CNV	Lu <i>et al.</i> (2015)	
Machine Learning	Known SL		
Bimodality	Expression DNA CNV Somatic Mutation	Wappett (2014) Wappett <i>et al.</i> (2016)	BImodal Subsetting ExPression (BiSEp)
Directional Chi-Square	Expression (microarray) Somatic mutation	Kelly, S. T., Guilford, P. J., and Black, M. A. Dissertation (Kelly, 2013) and developed here	SLIPT

different approach. Existing computational approaches to synthetic lethal prediction are often difficult to interpret, replicate for new genes, or are reliant on data types not available for a wider range of genes to test.

1.2.7.2 Comparative Genomics

A comparative genomics approach by Deshpande *et al.* (2013) used the results of well characterised high-throughput mutation screens in *S. cerevisiae* as candidates for synthetic lethality in humans (Baryshnikova *et al.*, 2010a; Costanzo *et al.*, 2010, 2011; Tong *et al.*, 2001, 2004). Yeast synthetic lethal partners were compared to human orthologues to find cancer relevant synthetic lethal candidate pairs with direct therapeutic potential. Proposed as a complementary approach to siRNA screens, approximately 24,000 of the 116,000 negative SGIs in yeast (Costanzo *et al.*, 2011) were matched to human orthologues, with over 500 involving a cancer gene (Futreal *et al.*, 2004). Under strict criteria of one-to-one orthologues, large effect size and significant interaction in yeast data ($\epsilon < -0.2$, $p < 0.05$), 1,522 interactions were identified with 70 involving cancer genes. Of the 21 gene interactions tested with pairs of siRNA in IMR1 fibroblast cells, 6 exhibited synthetic lethal effects. The two strongest interactions (*SMARCB1* with

PSMA4 and *ASPSCR1* with *PSMC2*) were successfully validated by protein analysis of human cells and replication with tetrad analysis for yeast orthologues.

Another approach to systematic synthetic lethality discovery specific to human cancer (in contrast to the plethora of yeast synthetic lethality data) was to build a database as done by Li *et al.* (2014). In their relational database, called “Syn-lethality”, they have curated both known experimentally discovered synthetic lethal pairs in humans (113 pairs) from the literature and those predicted from synthetic lethality between orthologous genes in *S. cerevisiae* yeast (1114 pairs). This knowledge-based database is the first dedicated to human cancer synthetic lethal interactions and integrates gene function annotation, pathway and molecular mechanism data with experimental and predicted synthetic lethal gene pairs. This combination of data sources is intended to tackle the trade-off between more conclusive synthetic lethal experiments in yeast and more clinically relevant synthetic lethal experiments in human cancer models, such as RNAi, especially when high-throughput screens are costly and prone to false positives in either system and difficult to replicate across gene backgrounds. This database centralises a wealth of knowledge scattered in the literature including cancer relevant genes (*BRCA1*, *BRCA2*, *PARP1*, *PTEN*, *VHL*, *MYC*, *EGFR*, *MSH2*, *KRAS*, and *TP53*) and is publicly available as a Java App. These included the previously mentioned interactions of *BRCA1* and *BRCA2* with *PARP1* and *TP53* with *WEE1* and *PLK1*. However, the computational methodology was not released, so it is not possible to replicate their results, nor to add to the findings with new datasets, which are limited to 647 human genes. Suggested future directions were promising, such as constructing networks of known synthetic lethality, applying known synthetic lethality to cancer treatment, data mining, replicating the approach for synthetic lethality in model organisms, signalling pathways, and developing a complete global network in human cancer or yeast (both of which are still incomplete with experimental data), some of which has been implemented in “SynLethDB” (Guo *et al.*, 2016).

Machine learning approaches have also been proposed for synthetic lethal discovery (Babyak, 2004; Lee and Marcotte, 2009). Due to concerns that these may be subject to overfitting or noise, Wu *et al.* (2014) developed a meta-analysis method (based on the machine learning methods in Table 1.3) for synthetic lethal gene pairs relevant to developing selective drugs against human cancer, building upon their previous database (Li *et al.*, 2014). They used training data of 10,885 synthetic lethal interactions from yeast experiments of which 7347 occurred between the 5,504 non-essential genes. Their “metaSL” approach utilises genomic, proteomic and annotation data (including GO

Table 1.3: Machine Learning Methods used by Wu *et al.* (2014)

Method	Source	Tool Offered
Random Forest	Breiman (2001)	
Random Forest		
J48 (decision tree)		
Bayes (Log Regression)		
Bayes (Network)	Hall <i>et al.</i> (2009)	WEKA
PART (Rule-based)		
RBF Network		
Bagging / Bootstrap		
Classification via Regression		
Support Vector Machine (Linear)	Vapnik (1995)	
Support Vector Machine (RBF – Gaussian)	Joachims (1999)	
Multi-Network Multi-Class (MNMC)	Pandey <i>et al.</i> (2010)	
MetaSL (Meta-Analysis)	Wu <i>et al.</i> (2014)	MetaSL

terms Ashburner *et al.* (2000), PPI, protein complexes, and biological pathway) with strong statistical performance in yeast data (AUROC of 0.871). The predicted orthologous synthetic lethal partners in human data were not experimentally validated but several would be relevant to cancer such as *EGFR* with *PRKCZ*. They note that computational approaches scale-up across the genome at lower cost than experimental screen and share their most supported interactions online. However, the method is not available for analysis of other genes studied by the cancer research community. While machine learning has great potential as a predictor, the results vary greatly depending on the predictive features selected and it is not clear which threshold should be used to report reliably detected genes. Syn-Lethality (Li *et al.*, 2014) and MetaSL (Wu *et al.*, 2014) demonstrate the value of computational approaches to synthetic lethality but omit many genes of importance in cancer, such as *CDH1*, and there remains a need to enable biological researchers to query such genes in a particular tissue or genetic background.

There is also concern for analyses based on yeast data that many synthetic lethal interactions may not be conserved between species Dixon *et al.* (2009), although interactions between pathways may be more comparable. It is unsurprising that many of the interactions identified were not experimentally validated. There have been many gene duplications in the separate evolutionary histories of humans and yeast which

may lead to differences in genetic redundancy. Yeast are not an ideal human cancer model because they do not have tissue specificity, multicellular gene regulation, or orthologues to a number of known cancer genes such as p53. Although these studies have tried to anticipate these issues with stringent criteria such as requiring one-to-one orthologues, there remains the possibility that changes in gene function may affect whether these are solely redundant such as if functions had coevolved without sequence homology. Many genes will also be excluded since they lack homologues in yeast, the corresponding experimental data, or having paralogues in either species. Thus conservation of yeast interactions is not an ideal strategy and analysis of human data directly for comparison with human experimental data will be the focus of this thesis.

1.2.7.3 Analysis and Modelling of Protein Data

Kranthi *et al.* (2013) took a network approach to discovery of synthetic lethal candidate selection applying the concept to “centrality” to a human PPI network involving interacting partners of known cancer genes. The effect of removing pairs of genes on connectivity of the network was used as a surrogate for viability which is supported by observations that the PPI and synthetic lethal networks are orthogonal in *S. cerevisiae* studies (Tong *et al.*, 2004). They showed that the human cancer protein interaction network (of 1539 proteins and 6471 interactions) exhibits the power law distribution expected of a scale-free synthetic lethal network with high connectivity (average vertex degree of 23.67 and network efficiency of 0.2952). Their top 100 candidate interactions included interactions of the tumour suppressor *TP53* with *BRCA1*, *CDKNA1*, *CDKNA2*, *MET*, and *RB1* which have been detected by prior studies. The gene pairs were often observed to be in the same or a plausible compensatory pathway. Thus the network structure is important in the biological functions of cancers and could be exploited for targeting *TP53* loss of function mutations.

However, their approach was limited to known cancer genes and is not applicable to genes that do not have PPI data. Other nucleotide sequencing data types are more commonly available for cancer studies at a genomic scale. Of further concern is that the results were enriched for p53 synthetic lethal partners which is relevant to many cancer researchers but this genome-wide approach did not detect many other cancer genes due to multiple testing. This enrichment may be due to the known drastic effect of removing p53 itself from the network as a master regulator, cancer driving tumour suppressor gene, and highly connected network “hub”. The focus on cancer genes is useful for translation into therapeutics but does not account for variable genetic backgrounds or effect of protein removal on the whole cellular network.

Focusing on the potential for synthetic lethality to be an effective anti-cancer drug target, Zhang *et al.* (2015) used modelling of signalling pathways to identify synthetic lethal interactions between known drug targets and cancer genes by simulating gene knockdowns. A computational approach was applied to avoid the limitations of experimental RNAi screens such as scale, instability of knockdown, and off-target effects. This ‘hybrid’ method of a data-driven model and known signalling pathways showed potential as a means to predict cell death in single and combination gene knockouts. They used time series protein phosphorylation data (Lee *et al.*, 2012) for 28 signalling proteins and Gene Ontology (GO) (GO) pathways Ashburner *et al.* (2000); Blake *et al.* (2015). This approach successfully detected many known essential genes in the human gene essentiality database, known synthetic lethal partners in the Syn-Lethality database (Li *et al.*, 2014), and predicted novel synthetic lethal gene pairs. The strongest essential genes in single knockdowns were *AKT*, *TP53*, *CHK1*, *S6K1*, and *CYCLIND1*. Pairwise knockdowns identified 252 candidate synthetic lethal interactions including *TP53* with *CHK1*, *S6K1*, *WEE1*, *CYCLIND1*, and *CASP9*; *AKT* with *WEE1*; and *CDK1* with *CYCLIND1*. These novel results contained many *TP53* and *AKT* synthetic lethal partners, genes known to be important in many cancers, however these also have a severe impact on the signalling pathways in their essentiality analysis of single gene disruptions and large phenotypic changes in cancer. This approach is amenable to detect functionally related pathways and protein complexes across the molecular function, cellular component, and biological process annotations provided by GO. The results were consistent with the experimental results in the literature but the novel synthetic lethal interactions have yet to be validated. While the mathematical reasoning and algorithms are given, the code was not released to replicate the findings or apply the methodology beyond the signalling pathways analysed by Zhang *et al.* (2015). While this is an interesting approach, the analysis of this thesis will focus on gene expression and RNAi data which is available to test a wider range of candidate gene pairs.

1.2.7.4 Differential Gene Expression

Differential gene expression has been explored to predict synthetic lethal pairs in cancer which would be widely applicable due to the availability of public gene expression data for a large number of samples and cancer types. Wang and Simon (2013) found differentially expressed genes (by the t-test, adjusted by FDR) between tumours with or without functional p53 mutations in TCGA (McLendon *et al.*, 2008) and Cancer Cell Line Encyclopaedia (CCLE) (Barretina *et al.*, 2012) RNA-Seq gene expression

data as candidate synthetic lethal partner pathways of p53. They identified 2, 8, and 21 candidate synthetic lethal partner genes in 3 microarray datasets from the NCI60 cell lines, 31 partner genes from the CCLE RNA-Seq data (Barretina *et al.*, 2012), and 50 in TCGA RNA-Seq data (Muzny *et al.*, 2012). *PLK1* was replicated across 4 of these analyses and 17 other genes were replicated across 2 analyses (including *MTOR*, *PLK4*, *MAST2*, *MAP3K4*, *AURKA*, *BUB1* and 6 CDK genes) with many playing a role in cell cycle regulation. This was supported by a drug sensitivity experiment on the NCI60 cell lines which found that cells which lacked functional p53 were more sensitive to paclitaxel (which targets *PLK1*, *AURKA*, and *BUB1*). This demonstrated the potential of gene expression as a surrogate for gene function and use of public genomic data to predict synthetic lethal gene pairs in cancer. Wang and Simon (2013) advocated for pre-screening of expression profiles to augment future RNAi screens. However, the analyses were limited to kinase genes and focused on currently druggable genes, lacking wider application of synthetic lethal prediction methodology. This approach may not be feasible or applicable in cancer genes with a lower mutation rate than p53.

Tiong *et al.* (2014) also investigated gene expression as a predictor of synthetic lethal pairs with colorectal cancer microarrays from a Han Chinese population with a sample size of 70 tumour and 12 normal tissue samples. Simultaneously differential expression of “tumour dependent” gene pairs (which includes co-expression) between cancer and normal tissue was used to rank 663 candidate synthetic lethal interactions identified in cell line siRNA experiments. Of the top 20 genes, 17 were tested for testing differential expression at the protein level with immunohistochemistry staining and correlation with clinical characteristics, with 11 pairs exhibiting synergistic effects. Some of the predicted synthetic lethal pairs were consistent with the literature (including *TP53* with *S6K1* and partners of *KRAS*, *PTEN*, *BRCA1*, and *BRCA2*) and two novel synthetic lethal interactions (*TP53* with *CSNK1E* and *CTNNB1*) were validated in pre-clinical models. This serves a valuable proof-of-concept for integration of *in silico* approaches to synthetic lethal discovery in cancer demonstrating its utility to triage and identify synthetic lethal partners of p53 applicable to colorectal tissues. Although the experimental work was the focus of the paper, these findings show that bioinformatics synthetic lethal candidates can be validated in patient tissue samples (from a non-caucasian population) to find those applicable to colorectal cancers.

1.2.7.5 Data Mining and Machine Learning

Recognising the utility of synthetic lethality to drug inhibition and specificity of anti-cancer treatments, Jerby-Arnon *et al.* (2014) also saw the need for effective prediction

of gene essentiality and synthetic lethality to augment experimental studies of SL. They developed the DAISY pipeline (DAISY), a data-driven approach for genome-wide analysis of synthetic lethality in public cancer genomics data from TCGA and CCLE (Barretina *et al.*, 2012). DAISY is intended to predict the candidate synthetic lethal partners of a query gene such as genes recurrently mutated in cancer.

Jerby-Arnon *et al.* (2014) combined a computational approach to triage candidates with a conventional RNAi screen to validate synthetic lethal partners. They screened a selection of computationally predicted candidates and randomly selected genes with RNAi against *VHL* loss of function mutation in RCC4 renal cell lines. The computational method had a high AUROC of 0.779 and predictions were enriched 4× for validated RNAi hits over randomly selected genes. This approach detected known synthetic lethal pairs such as *BRCA1* or *BRCA2* genes with *PARP1* and *MSH2* with *DHFR*. The synthetic lethal candidates identified with both RNAi screening and computational prediction formed an extensive network of 2077 genes with 2816 synthetic lethal interactions and similar network of 3158 genes with 3635 synthetic dosage lethal interactions (for synthetic lethality with over-expression). Each network was scale-free as expected of a biological network and was enriched for known cancer genes, essential genes in mice, and could be harnessed for predicting prognosis and drug response. While demonstrating the feasibility of combining experimental and computational approaches to synthetic lethality in cancer, there remain challenges in predicting synthetic lethal genes, novel drug targets, and translation into the clinic.

The DAISY methodology (Jerby-Arnon *et al.*, 2014) compares the results of analysis of several data types to predict synthetic lethality, namely: DNA copy number and somatic mutation for TCGA patient samples and CCLE cell lines. The cell lines were also analysed with gene expression and gene essentiality (shRNA screening) profiles. Genes were classed as inactivated by copy number deletion, somatic loss of function mutation, or low expression and tested for synthetic lethal gene partners which are either essential in screens or not deleted with copy number variants. Co-expression is also used for synthetic lethality prediction based on studies in yeast (Costanzo *et al.*, 2010; Kelley and Ideker, 2005). Copy number, gene expression and, essentiality analyses are stringently compared by adjusting each for multiple tests with Bonferroni correction and only taking hits which occur in all analyses. This methodology was also adapted for synthetic dosage lethality by testing for partner genes where genes are overactive with high copy number or expression. As discussed above, the predictions performed

well and an RNAi screen for the example of *VHL* in renal cancer validated predicted synthetic lethal partners of *VHL* demonstrating the feasibility of combining approaches to synthetic lethal discovery in cancer and using computational predictions to enable more efficient high-throughput screening. DAISY performs well statistically with a AUROC of 0.779 on a set of gene pairs with experimental screen data, although co-expression and shRNA functional examination contributes much less of this than the mutation and copy number analysis (AUROC 0.683 alone). However, this methodology is very stringent, missing potentially valuable synthetic lethal candidates, may not be applicable to genes of interest to other groups and the software for the procedure has not been publicly released for replication.

Although the DAISY procedure performs well and has been well received by the scientific community (Crunkhorn, 2014; Lokody, 2014; Ryan *et al.*, 2014), showing a need for such methodology, there is no indication of adoption of the methodology in the community yet. The co-expression analysis may not be the most effective way to test gene expression for directional synthetic lethal interactions (where inverse correlation would be expected). In the interests of a large sample size, tissue types were not tested separately despite tissue-specific synthetic lethality being likely since gene function (and by extension expression, isoforms, and clinical characteristics) in cancers may often be tissue-dependent. Some data forms and analyses used, such as gene essentiality, may not be available for all cancers, genes, or tissues, and may not be reproduced.

Lu *et al.* (2015) critique the assumption of co-expression in the DAISY methodology and propose an alternative computational prediction of synthetic lethality based on machine learning methods and a “cancer genome evolution” hypothesis. Using DNA copy number and gene expression data from TCGA patient samples, a cancer genome evolution model assumes that synthetic lethal gene pairs behave in two distinct ways in response to an inactive synthetic lethal partner gene, either a “compensation” pattern where the other synthetic lethal partner is overactive or a “co-loss underrepresentation” pattern where the other synthetic lethal partner is less likely to be lost, since loss of both genes would cause death of the cancer cell. During the genome evolution of cancers, the cell becomes addicted to the remaining synthetic lethal partner due to induced gene essentiality. These patterns would explain why DAISY detects only a small number of synthetic lethal pairs, compared to the large number expected based on model organism studies (Boone *et al.*, 2007), and the disparity between screening and computationally predicted synthetic lethal candidates due to testing different classes of synthetic lethal gene pairs.

Lu *et al.* (2015) compared a genome-wide computational model of genome evolution and gene expression patterns to the experimental data of Vizeacoumar *et al.* (2013) and Laufer *et al.* (2013). This simpler model performing well with an AUROC of 0.751 but was less than DAISY, although it did not rely on data from cell lines which may not represent patient disease. They predict a larger comprehensive list of 591,000 human synthetic lethal partners with a probability score threshold of 0.81, giving a precision of 67% and $14\times$ enrichment of synthetic lethal true positives compared to randomly selected gene pairs. Discovery of such a vast number of cancer-relevant synthetic lethal interactions in humans would not be feasible experimentally and is a valuable resource for research and clinical applications. These predictions are not limited by assuming co-expression of synthetic lethal partners or evolutionary conservation with model organisms enabling wider synthetic lethal discovery. However, there remains a lack of basis for an expectation of how many synthetic lethal partners a particular gene will have, how many pairs there are in the human genome, and whether pathways or correlation structure would influence predicted synthetic lethal partners.

Large scale, computational approaches have yet to determine whether synthetic lethal interactions are tissue-specific since Lu *et al.* (2015) used pan-cancer data for 14136 patients with 31 cancer types. Experimental data used for comparison was a small training dataset specific to colorectal cancer, and based on screens for other phenotypes, which may limit performance of the model or application to other cancers. Proposed expansion of the computational approach to mutation, microRNA, or epigenetic modulation of gene function and tumour micro-environment or heterogeneity suggests that synthetic lethal discovery could be widely applied to the current challenges in cancer genomics. This approach was also based on machine learning methodology and not supported by a software release for the community to develop, contribute to, or reproduce beyond the gene pairs given in the supplementary results.

1.2.7.6 Bimodality

Wappett *et al.* (2016) demonstrate a multi-omic approach to identification of synthetic lethality in cancer with a strategy to detect bimodal patterns in molecular profiles. They released this solution as the BiSEp R package Wappett (2014) which aims to detect subtle bimodal and non-normal patterns in expression data. Since loss of gene function is not consistently genetic, Wappett *et al.* (2016) advocate the use of gene expression (loss of mRNA) and deletion (loss of copy number) data in addition to mutation. The BiSEp procedure was demonstrated on an analysis of 881 cell lines from CCLE (Barretina *et al.*, 2012), 442 cell lines from Catalogue Of Somatic Mutations In

Cancer (COSMIC) (Forbes *et al.*, 2015), and RSEM normalised RNA-Seq data for 178 TCGA lung patient samples (Collisson *et al.*, 2014). BiSEp was demonstrated to have significant enrichment of validated tumour suppressor, synthetic lethal gene pairs (detecting 76 experimentally supported gene pairs) and was improved (detecting 420) with expression data rather than relying on detecting loss of gene function by mutation or deletion. They identified interactions with genes relevant to cancer with support in experimental screens including *ERCC4* with *XRCC1*, *BRCA1* with *PARP3*, and *SMARCA1* with *SMARCA4*.

Wappett *et al.* (2016) demonstrated that analysis of genomics data, particularly expression data, is relevant to augment the identification of synthetic lethal interactions with screening experiments. They further show that this is applicable in both genetically homogeneous cell lines and heterogeneous cell population from patient samples. This approach is limited however to genes which exhibit bimodal expression patterns which do not commonly occur, particularly in normalised gene expression data, and other approaches may need to be considered for gene such as *CDH1* which were not identified by BiSEp.

1.2.7.7 Rationale for Further Development

Many of the approaches discussed here aimed to identify the strongest synthetic lethal pairs across the yeast or human genomes (Deshpande *et al.*, 2013; Lu *et al.*, 2015; Wappett *et al.*, 2016; Wu *et al.*, 2014), which may not be an ideal strategy to identify interactions in particular functions or relevance to particular cancers. These demonstrate a need for computational approaches to prioritise candidate gene pairs for validation but this thesis will focus on the interactions with *CDH1* with particular importance in breast and stomach cancers, although these partners may be applicable in other cancers. As such, this thesis presents a query-based method, amenable to identification of candidate partners for a selected gene of functional or translational importance such as *CDH1*.

1.3 E-cadherin as a Synthetic Lethal Target

E-cadherin is a transmembrane protein (encoded by *CDH1*) with several characterised functions in the cytoskeleton and cell-to-cell signalling. Here we outline the key known functions of E-cadherin and it's importance in cancer biology. *CDH1* is a tumour suppressor gene, with loss of function occurring in both familial (germline mutations) and sporadic (somatic mutations) cancers. As such, *CDH1* inactivation is a prime example of a genetic event that could be targeted by synthetic lethality for anti-cancer

treatments. Most notably this includes patients at risk of developing hereditary breast and stomach cancers for which conventional surgical or cytotoxic chemotherapy is not ideal (due to impact of quality of life) and who have a known genetic aberration in their familial syndromic cancers. Effective treatments against *CDH1* inactivation would also benefit patients with sporadic diffuse gastric cancers since they often present with symptoms at a late stage.

1.3.1 The *CDH1* gene and it's Biological Functions

The tumour suppressor gene *CDH1* is implicated in hereditary and sporadic lobular breast cancers (Berx *et al.*, 1996; Berx and van Roy, 2009; De Leeuw *et al.*, 1997; Masciari *et al.*, 2007; Semb and Christofori, 1998; Vos *et al.*, 1997). The *CDH1* gene encodes the E-cadherin protein and is normally expressed in epithelial tissues, where it has also been identified as an invasion suppressor and loss of *CDH1* function has been implicated in breast cancer progression and metastasis (Becker *et al.*, 1994; Berx *et al.*, 1995; Christofori and Semb, 1999).

1.3.1.1 Cytoskeleton

The primary function of *CDH1* is cell-cell adhesion forming the adherens junction, maintaining the cytoskeleton and mediating molecular signals between cells. The function of the adherens complex is particularly important for cell structure and regulation because it interacts with cytoskeletal actins and microtubules. The cytoskeletal role of E-cadherin maintains healthy cellular viability and growth in epithelial tissues including cellular polarity. E-cadherin is not essential to cellular viability but loss in epithelial cells does lead to defects in cytoskeletal structure and proliferation. In addition to a central role in the adherens complex, E-cadherin is involved in many other cellular functions and thus *CDH1* is regarded as a highly pleiotropic gene.

1.3.1.2 Extracellular and Tumour Micro-Environment

As a transmembrane signalling protein E-cadherin also interacts with the extracellular environment and other cells, most notably forming tight junctions between cells. These junctions serve to both regulate movement of ion signals between cells and separate membrane proteins on the apical and basal surfaces of a cell, maintaining cell polarity. Thus E-cadherin is an important regulator of epithelial tissues by intercellular communication. It also has important roles in the extracellular matrix, including fibrin clot formation. The role of intercellular interactions and the tissue micro-environment are important themes in cancer research, being a potential mechanism for cancer progres-

sion and malignancy in addition to its potential for specifically targeting tumour cells.

1.3.1.3 Cell-Cell Adhesion and Signalling

The signals mediated by tight junctions are also passed on to intracellular signalling pathways and thus E-cadherin also has a role in maintaining cellular function and growth. One such example is the regulation of β -catenin which interacts with both the actin cytoskeleton and acts as a transcription factor via the WNT pathway. Similarly, the Hippo and PI3K/AKT pathways are implicated in being mediated by E-cadherin, having roles in promoting cell survival, proliferation, and repressing apoptosis. E-cadherin shares several downstream pathways with signalling pathways such as integrins and thus indirectly interacts with them, particularly since feedback loops may occur in such pathways. Conversely, the multifaceted roles of E-cadherin have been shown with differing overexpression in ovarian cells promoting tumour growth, while it maintains healthy cellular functions in other cells.

1.3.2 *CDH1* as a Tumour (and Invasion) Suppressor

E-cadherin has key roles in maintaining cellular structure and regulating growth, consistent with *CDH1* being a tumour suppressor gene. Loss of *CDH1* in epithelial tissues leads to disrupted cell polarity, differentiation, and migration. E-cadherin loss has been identified as a recurrent driver tumour suppressor mutation in sporadic cancers of many tissues including breast, stomach, lung, colon, and pancreas tissue.

1.3.2.1 Breast Cancers and Invasion

E-cadherin loss in breast cancers has been shown to cause increased proliferation, lymph node invasion, and metastasis with poor cell-cell contact. Thus *CDH1* gene has also been implicated as an invasion suppressor, with a key role in the epithelial-mesenchymal transition (EMT), an established mechanism of cancer progression (Hanahan and Weinberg, 2011). The epithelial-mesenchymal transition is important during development and wound healing but such changes in cellular differentiation also occur in cancers. If *CDH1* is inactivated by mutation or DNA methylation (Berx *et al.*, 1996; Guilford, 1999; Machado *et al.*, 2001), it is likely that EMT will drive growth of E-cadherin deficient cancers (Berx and van Roy, 2009; Graziano *et al.*, 2003; Polyak and Weinberg, 2009). While loss of E-cadherin is not sufficient to cause EMT or tumourigenesis, it is an important step in this mechanism of tumour progression and a potential therapeutic

intervention may therefore also impede cancer progression and have activity against advanced stage cancers.

1.3.3 Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer

CDH1 loss of function mutations also causes familial cancers, including diffuse gastric cancer and lobular breast cancer (Graziano *et al.*, 2003; Guilford *et al.*, 2010, 1999; Oliveira *et al.*, 2009). Individuals carrying a null mutation in *CDH1* have a syndromic predisposition to early-onset these cancers, known as hereditary diffuse gastric cancer (HDGC) (Guilford *et al.*, 1998). Due to the loss of an allele, these individuals are prone to carcinogenic lesion in the breast and stomach when the other allele is inactivated, occurring much more frequently and thus younger than in individuals without a second functional allele of *CDH1*. The loss of the second allele is most often hypermethylation suppressing expression rather than mutation, although loss of heterozygosity may also occur. Therefore HDGC is an autosomal dominant cancer syndrome with incomplete penetrance. The “lifetime” (until age 80 years) risk for mutation carriers of diffuse gastric cancer is 70% in males and 56% in females. In addition, the lifetime risk of lobular breast cancer is 42% in female mutation carriers.

HDGC affects less than 1 in a million people globally (Ferlay *et al.*, 2015) and less than 1% of gastric cancers. However, HDGC is documented to affect several hundred families globally. E-cadherin mutations in the germline is implicated in 1-3% of gastric cancers presenting with a family history, varying between high and low incidence populations. E-cadherin is also mutated in 13% of sporadic gastric cancers.

While diagnostic testing for *CDH1* genotype has enabled more effective management of HDGC and improved patient outcomes, there are still limited options for clinical interventions (Guilford *et al.*, 2010). Individuals with a family history of HDGC are recommended to be tested for *CDH1* mutations in late adolescence and are offered prophylactic stomach surgery before the risk of developing cancers increases with age. Another option is annual endoscopic screening to diagnose early stage stomach cancers with surgical intervention once they are detected (Oliveira *et al.*, 2013). However, these early stage cancers are difficult to detect and may be missed in regular screening. Thus patients carrying *CDH1* mutations either have surgical interventions with a significant impact on quality of life and risk of complications or remain at risk of developing advanced stage stomach cancers. Due to the lower mortality rate due to stomach cancers,

there is increasing concerns among these HDGC families on the elevated risk of lobular breast cancers for women later in life.

The current clinical management of HDGC still has significant risks for patients and therefore a greater understanding of the molecular and cellular function of *CDH1* is important for its role in these cancers. Such studies may lead to alternative treatment strategies such as pharmacological treatments with specificity against *CDH1* null cells, once they lose the second allele. While a loss of gene function cannot be targeted directly, designing a treatment with specificity against *CDH1* may also have activity in sporadic cancers in a range of epithelial cancers. Thus an effective treatment against *CDH1* mutant cancers would potentially have significant therapeutic and preventative applications in a large number of patients.

1.3.4 Models of *CDH1* loss in cell lines

Previous work our research group has published used a model of homozygous *CDH1*^{-/-} null mutation in non-malignant MCF10A breast cells to show that loss of *CDH1* alone was not sufficient to induce EMT with compensatory changes in the expression of other cell adhesion genes occurring (Chen *et al.*, 2014). However, *CDH1* deficient cells did manifest changes in morphology, migration, and weaker cell adhesion (Chen *et al.*, 2014).

This *CDH1*^{-/-} MCF10A model has been used in a genome-wide screen of 18,120 genes using short interfering ribonucleic acid (siRNA) and a complementary drug screen using 4,057 compounds to identify synthetic lethal partners to E-cadherin (Telford *et al.*, 2015). One of the strongest candidate pathways identified by Telford *et al.* (2015) were the GPCR signalling cascades, which were highly enriched by GO analysis of the candidate synthetic lethal partners the primary siRNA screen. This was supported by validation with Pertussis toxin, known to target G_{αi} signalling (Clark, 2004), as were various candidate cytoskeletal pathways by inhibition of Janus kinase (JAK) and aurora kinase. The drug screen also produced candidates in histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) which were supported by validation and time course experiments.

1.4 Summary and Research Direction of Thesis

Genomics technologies and the data available from them have immense potential for understanding of genetics and improving healthcare, including identification of genes altered in cancer for molecular diagnosis, prognostic biomarkers, and therapeutic targets.

This has been demonstrated with the identification of cancer genes in many cancers, distinguishing tumour subtypes by expression profiles, and the development of targeted therapies against oncogenes (such as *BRAF*) and tumour suppressors (such as *BRCA1*). Synthetic lethality is an important genetic interaction to study fundamental cellular functions and exploit them for biomarkers and cancer treatment. They present a means to target loss of function mutations and genetic dysregulation in tumour suppressor genes by identifying interacting partners with redundant or compensating molecular functions.

CDH1 (encoding E-cadherin) is an example of a tumour suppressor gene implicated in sporadic breast and stomach cancers. Germline mutations in *CDH1* are also found in many patients with familial early onset cancers (HDGC). Discovery of synthetic lethal partners would be contribute to an understanding on the molecular mechanisms driving the growth of *CDH1* deficient tumours and identification of potential therapeutic targets or chemopreventative agents for management of HDGC. The clinical potential of the synthetic lethal approach has been demonstrated with the application of olaparib against *BRCA1* and *BRCA2* mutations Lord *et al.* (2015) but there remains the need to systematically identify synthetic lethal partner genes for other tumour suppressors such as *CDH1*. A synthetic lethal screen has been conducted on breast cell lines Telford *et al.* (2015) but computational approaches to identification of synthetic lethal partners of *CDH1* remains to be done.

While there are a wide range of experimental and computational approaches to synthetic lethal discovery, many are limited to particular applications, prone to false positives, inconsistent across independent approaches, or enriched for particular genes of interest. Therefore synthetic lethal interactions are difficult to replicate or apply in the clinic. Computational approaches to synthetic lethality are not widely adopted by the cancer research community and experimental approaches cannot be combined to study synthetic lethality at a genome-wide scale. However, these show interest in synthetic lethal discovery in the community and the need for robust predictions of synthetic lethal interactions in cancer and human tissues.

Effective screening, prediction, and analysis of synthetic lethal interactions are a crucial part of developing next generation anti-cancer strategies. Therefore, we propose developing a computational statistical procedure to identify synthetic lethal interactions and construct gene networks. This will enable the development of personalised medicine targeted to particular molecular aberrations. Genetic tests and genomics have the potential to revolutionise cancer screening, diagnosis, and prognostics; tar-

geted therapeutics, similarly, have applications in prevention and therapy of sporadic or hereditary cancers with known molecular properties.

To address the concerns raised by recent computational approaches to synthetic lethal discovery in cancer (Jerby-Arnon *et al.*, 2014; Lu *et al.*, 2015; Wappett *et al.*, 2016), I present similar analysis using solely gene expression data which is widely available for a large number of samples in many different cancers. This uses a statistical methodology the Synthetic Lethal Interaction Prediction Tool (SLIPT) developed for this purpose. To further determine the limitations and implications of synthetic lethal predictions, modelling and simulation was performed upon the statistical behaviour of synthetic lethal gene pairs in genomics data. Comparison of synthetic lethal gene candidates from public data analysis and experimental candidates, pathway analysis, and networks structure will also be presented to investigate the relationships between synthetic lethal candidates. Release of R codes used for simulation, prediction, and analysis will enable adoption of the methodology in the cancer research community and comparison to existing methods. Therefore my thesis aims to develop such predictions for synthetic lethal partner genes with a focus on the example of E-cadherin to compare to the findings of Telford *et al.* (2015), develop of network approaches for pathway structure, and simulate gene expression on pathway structure with the bioinformatics and computational biology investigations.

1.4.1 Thesis Aims

Understanding synthetic lethality is important in cancers and has shown an impact clinical practice and patient outcomes for certain genes already. Thus this thesis aims to identify synthetic lethal gene pairs using public gene expression data. Accordingly, chapter 3 aims to develop the methods to do so including a synthetic lethal detection methodology (SLIPT) which has been released as an R software package. This chapter also documents the simulation and network analysis procedures developed to support the use of SLIPT and perform analyses in throughout this thesis.

This thesis also aimed to demonstrate SLIPT methodology for analysis of RNA-Seq gene expression data. Chapter 4 aimed to do so by performing an analysis to identify candidate synthetic lethal gene partners of *CDH1* in public breast and stomach cancer data (Bass *et al.*, 2014; TCGA, 2012). Chapter 4 also aimed to demonstrate the biological relevance of these candidate synthetic lethal partners by identifying synthetic lethal pathways and comparing them with the results of an experimental siRNA screen (Telford *et al.*, 2015).

Pathway analysis was extended with graph structures in chapter 5 which aimed to assess the importance of synthetic lethal genes within pathway structures. Chapter 5 also aimed to use pathway structure to identify directional relationships between SLIPT and siRNA synthetic lethal candidates and explore the disparity between them. The SLIPT methodology was also supported by simulations investigations in chapters 3 and 6 which aimed to evaluate the SLIPT method on detecting known synthetic lethal genes in simulated data. Graph structures were also used in chapter 6 which also aimed to determine the effect of pathway structures of synthetic lethal detection with SLIPT in simulated data and ascertain that the simulation results were comparable to expression data with contains complex correlation structures within biological pathways.

References

- Aarts, M., Bajrami, I., Herrera-Abreu, M.T., Elliott, R., Brough, R., Ashworth, A., Lord, C.J., and Turner, N.C. (2015) Functional genetic screen identifies increased sensitivity to weel inhibition in cells with defects in fanconi anemia and hr pathways. *Mol Cancer Ther*, **14**(4): 865–76.
- Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C.D., Annala, M., Aprikian, A., Armenia, J., Arora, A., *et al.* (2015) The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **163**(4): 1011–1025.
- Adamski, M.G., Gumann, P., and Baird, A.E. (2014) A method for quantitative analysis of standard and high-throughput qPCR expression data based on input sample quantity. *PLoS ONE*, **9**(8): e103917.
- Adler, D. (2005) *vioplot: Violin plot*. R package version 0.2.
- Agarwal, S., Deane, C.M., Porter, M.A., and Jones, N.S. (2010) Revisiting date and party hubs: Novel approaches to role assignment in protein interaction networks. *PLoS Comput Biol*, **6**(6): e1000817.
- Agrawal, N., Akbani, R., Aksoy, B.A., Ally, A., Arachchi, H., Asa, S.L., Auman, J.T., Balasundaram, M., Balu, S., Baylin, S.B., *et al.* (2014) Integrated genomic characterization of papillary thyroid carcinoma. *Cell*, **159**(3): 676–690.
- Akbani, R., Akdemir, K.C., Aksoy, B.A., Albert, M., Ally, A., Amin, S.B., Arachchi, H., Arora, A., Auman, J.T., Ayala, B., *et al.* (2015) Genomic Classification of Cutaneous Melanoma. *Cell*, **161**(7): 1681–1696.
- Akobeng, A.K. (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. *Acta Paediatrica*, **96**(5): 644–647.
- American Cancer Society (2017) Genetics and cancer. <https://www.cancer.org/cancer/cancer-causes/genetics.html>. Accessed: 22/03/2017.

- American Society for Clinical Oncology (ASCO) (2017) The genetics of cancer. <http://www.cancer.net/navigating-cancer-care/cancer-basics/genetics/genetics-cancer>. Accessed: 22/03/2017.
- Anjomshoaa, A., Lin, Y.H., Black, M.A., McCall, J.L., Humar, B., Song, S., Fukuzawa, R., Yoon, H.S., Holzmann, B., Friederichs, J., *et al.* (2008) Reduced expression of a gene proliferation signature is associated with enhanced malignancy in colon cancer. *Br J Cancer*, **99**(6): 966–973.
- Araki, H., Knapp, C., Tsai, P., and Print, C. (2012) GeneSetDB: A comprehensive meta-database, statistical and visualisation framework for gene set analysis. *FEBS Open Bio*, **2**: 76–82.
- Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., *et al.* (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet*, **25**(1): 25–29.
- Ashworth, A. (2008) A synthetic lethal therapeutic approach: poly(adp) ribose polymerase inhibitors for the treatment of cancers deficient in dna double-strand break repair. *J Clin Oncol*, **26**(22): 3785–90.
- Audeh, M.W., Carmichael, J., Penson, R.T., Friedlander, M., Powell, B., Bell-McGuinn, K.M., Scott, C., Weitzel, J.N., Oaknin, A., Loman, N., *et al.* (2010) Oral poly(adp-ribose) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and recurrent ovarian cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 245–51.
- Babyak, M.A. (2004) What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. *Psychosom Med*, **66**(3): 411–21.
- Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P.A., Stratton, M.R., *et al.* (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. *Br J Cancer*, **91**(2): 355–358.
- Barabási, A.L. and Albert, R. (1999) Emergence of scaling in random networks. *Science*, **286**(5439): 509–12.

- Barabási, A.L., Gulbahce, N., and Loscalzo, J. (2011) Network medicine: a network-based approach to human disease. *Nat Rev Genet*, **12**(1): 56–68.
- Barabási, A.L. and Oltvai, Z.N. (2004) Network biology: understanding the cell’s functional organization. *Nat Rev Genet*, **5**(2): 101–13.
- Barrat, A. and Weigt, M. (2000) On the properties of small-world network models. *The European Physical Journal B - Condensed Matter and Complex Systems*, **13**(3): 547–560.
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., *et al.* (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*, **483**(7391): 603–607.
- Barry, W.T. (2016) *safe: Significance Analysis of Function and Expression*. R package version 3.14.0.
- Baryshnikova, A., Costanzo, M., Dixon, S., Vizeacoumar, F.J., Myers, C.L., Andrews, B., and Boone, C. (2010a) Synthetic genetic array (sga) analysis in *saccharomyces cerevisiae* and *schizosaccharomyces pombe*. *Methods Enzymol*, **470**: 145–79.
- Baryshnikova, A., Costanzo, M., Kim, Y., Ding, H., Koh, J., Toufighi, K., Youn, J.Y., Ou, J., San Luis, B.J., Bandyopadhyay, S., *et al.* (2010b) Quantitative analysis of fitness and genetic interactions in yeast on a genome scale. *Nat Meth*, **7**(12): 1017–1024.
- Bass, A.J., Thorsson, V., Shmulevich, I., Reynolds, S.M., Miller, M., Bernard, B., Hinoue, T., Laird, P.W., Curtis, C., Shen, H., *et al.* (2014) Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*, **513**(7517): 202–209.
- Bates, D. and Maechler, M. (2016) *Matrix: Sparse and Dense Matrix Classes and Methods*. R package version 1.2-7.1.
- Bateson, W. and Mendel, G. (1909) *Mendel’s principles of heredity*, by W. Bateson. University Press, Cambridge [Eng.].
- Beck, T.F., Mullikin, J.C., and Biesecker, L.G. (2016) Systematic Evaluation of Sanger Validation of Next-Generation Sequencing Variants. *Clin Chem*, **62**(4): 647–654.

- Becker, K.F., Atkinson, M.J., Reich, U., Becker, I., Nekarda, H., Siewert, J.R., and Hfler, H. (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Research*, **54**(14): 3845–3852.
- Bell, D., Berchuck, A., Birrer, M., Chien, J., Cramer, D., Dao, F., Dhir, R., DiSaia, P., Gabra, H., Glenn, P., *et al.* (2011) Integrated genomic analyses of ovarian carcinoma. *Nature*, **474**(7353): 609–615.
- Benjamini, Y. and Hochberg, Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society Series B (Methodological)*, **57**(1): 289–300.
- Berx, G., Cleton-Jansen, A.M., Nollet, F., de Leeuw, W.J., van de Vijver, M., Cornelisse, C., and van Roy, F. (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. *EMBO J*, **14**(24): 6107–15.
- Berx, G., Cleton-Jansen, A.M., Strumane, K., de Leeuw, W.J., Nollet, F., van Roy, F., and Cornelisse, C. (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene*, **13**(9): 1919–25.
- Berx, G. and van Roy, F. (2009) Involvement of members of the cadherin superfamily in cancer. *Cold Spring Harb Perspect Biol*, **1**: a003129.
- Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih Ie, M., Conejo-Garcia, J.R., *et al.* (2015) Synthetic lethality by targeting ezh2 methyltransferase activity in arid1a-mutated cancers. *Nat Med*, **21**(3): 231–8.
- Blake, J.A., Christie, K.R., Dolan, M.E., Drabkin, H.J., Hill, D.P., Ni, L., Sitnikov, D., Burgess, S., Buza, T., Gresham, C., *et al.* (2015) Gene Ontology Consortium: going forward. *Nucleic Acids Res*, **43**(Database issue): D1049–1056.
- Boettcher, M., Lawson, A., Ladenburger, V., Fredebohm, J., Wolf, J., Hoheisel, J.D., Frezza, C., and Shlomi, T. (2014) High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells. *BMC Genomics*, **15**: 158.
- Boone, C., Bussey, H., and Andrews, B.J. (2007) Exploring genetic interactions and networks with yeast. *Nat Rev Genet*, **8**(6): 437–49.

- Borgatti, S.P. (2005) Centrality and network flow. *Social Networks*, **27**(1): 55 – 71.
- Boucher, B. and Jenna, S. (2013) Genetic interaction networks: better understand to better predict. *Front Genet*, **4**: 290.
- Breiman, L. (2001) Random forests. *Machine Learning*, **45**(1): 5–32.
- Brin, S. and Page, L. (1998) The anatomy of a large-scale hypertextual web search engine. *Computer Networks and ISDN Systems*, **30**(1): 107 – 117.
- Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005) Specific killing of *BRCA2*-deficient tumours with inhibitors of polyadprribose polymerase. *Nature*, **434**(7035): 913–7.
- Burk, R.D., Chen, Z., Saller, C., Tarvin, K., Carvalho, A.L., Scapulatempo-Neto, C., Silveira, H.C., Fregnani, J.H., Creighton, C.J., Anderson, M.L., *et al.* (2017) Integrated genomic and molecular characterization of cervical cancer. *Nature*, **543**(7645): 378–384.
- Bussey, H., Andrews, B., and Boone, C. (2006) From worm genetic networks to complex human diseases. *Nat Genet*, **38**(8): 862–3.
- Butland, G., Babu, M., Diaz-Mejia, J.J., Bohdana, F., Phanse, S., Gold, B., Yang, W., Li, J., Gagarinova, A.G., Pogoutse, O., *et al.* (2008) esga: E. coli synthetic genetic array analysis. *Nat Methods*, **5**(9): 789–95.
- Cancer Research UK (2017) Family history and cancer genes. <http://www.cancerresearchuk.org/about-cancer/causes-of-cancer/inherited-cancer-genes-and-increased-cancer-risk/family-history-and-inherited-cancer-genes>. Accessed: 22/03/2017.
- cBioPortal for Cancer Genomics (cBioPortal) (2017) cBioPortal for Cancer Genomics. <http://www.cbioportal.org/>. Accessed: 26/03/2017.
- Cerami, E.G., Gross, B.E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G.D., and Sander, C. (2011) Pathway Commons, a web resource for biological pathway data. *Nucleic Acids Res*, **39**(Database issue): D685–690.
- Chen, A., Beetham, H., Black, M.A., Priya, R., Telford, B.J., Guest, J., Wiggins, G.A.R., Godwin, T.D., Yap, A.S., and Guilford, P.J. (2014) E-cadherin loss alters

- cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. *BMC Cancer*, **14**(1): 552.
- Chen, S. and Parmigiani, G. (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol*, **25**(11): 1329–1333.
- Chen, X. and Tompa, M. (2010) Comparative assessment of methods for aligning multiple genome sequences. *Nat Biotechnol*, **28**(6): 567–572.
- Cherniack, A.D., Shen, H., Walter, V., Stewart, C., Murray, B.A., Bowlby, R., Hu, X., Ling, S., Soslow, R.A., Broaddus, R.R., *et al.* (2017) Integrated Molecular Characterization of Uterine Carcinosarcoma. *Cancer Cell*, **31**(3): 411–423.
- Chipman, K. and Singh, A. (2009) Predicting genetic interactions with random walks on biological networks. *BMC Bioinformatics*, **10**(1): 17.
- Christofori, G. and Semb, H. (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. *Trends in Biochemical Sciences*, **24**(2): 73 – 76.
- Ciriello, G., Gatz, M.L., Beck, A.H., Wilkerson, M.D., Rhie, S.K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., *et al.* (2015) Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell*, **163**(2): 506–519.
- Clark, M.J. (2004) Endogenous Regulator of G Protein Signaling Proteins Suppress G o-Dependent μ -Opioid Agonist-Mediated Adenylyl Cyclase Supersensitization. *Journal of Pharmacology and Experimental Therapeutics*, **310**(1): 215–222.
- Clough, E. and Barrett, T. (2016) The Gene Expression Omnibus Database. *Methods Mol Biol*, **1418**: 93–110.
- Collingridge, D.S. (2013) A primer on quantitized data analysis and permutation testing. *Journal of Mixed Methods Research*, **7**(1): 81–97.
- Collins, F.S. and Barker, A.D. (2007) Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. *Sci Am*, **296**(3): 50–57.
- Collins, F.S., Morgan, M., and Patrinos, A. (2003) The Human Genome Project: lessons from large-scale biology. *Science*, **300**(5617): 286–290.

- Collisson, E., Campbell, J., Brooks, A., Berger, A., Lee, W., Chmielecki, J., Beer, D., Cope, L., Creighton, C., Danilova, L., *et al.* (2014) Comprehensive molecular profiling of lung adenocarcinoma. *Nature*, **511**(7511): 543–550.
- Corcoran, R.B., Ebi, H., Turke, A.B., Coffee, E.M., Nishino, M., Cogdill, A.P., Brown, R.D., Della Pelle, P., Dias-Santagata, D., Hung, K.E., *et al.* (2012) Egfr-mediated reactivation of mapk signaling contributes to insensitivity of *BRAF*-mutant colorectal cancers to raf inhibition with vemurafenib. *Cancer Discovery*, **2**(3): 227–235.
- Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E.D., Sevier, C.S., Ding, H., Koh, J.L., Toufighi, K., Mostafavi, S., *et al.* (2010) The genetic landscape of a cell. *Science*, **327**(5964): 425–31.
- Costanzo, M., Baryshnikova, A., Myers, C.L., Andrews, B., and Boone, C. (2011) Charting the genetic interaction map of a cell. *Curr Opin Biotechnol*, **22**(1): 66–74.
- Courtney, K.D., Corcoran, R.B., and Engelman, J.A. (2010) The PI3K pathway as drug target in human cancer. *J Clin Oncol*, **28**(6): 1075–1083.
- Creighton, C.J., Morgan, M., Gunaratne, P.H., Wheeler, D.A., Gibbs, R.A., Robertson, A., Chu, A., Beroukhim, R., Cibulskis, K., Signoretti, S., *et al.* (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*, **499**(7456): 43–49.
- Croft, D., Mundo, A.F., Haw, R., Milacic, M., Weiser, J., Wu, G., Caudy, M., Garapati, P., Gillespie, M., Kamdar, M.R., *et al.* (2014) The Reactome pathway knowledge-base. *Nucleic Acids Res*, **42**(database issue): D472D477.
- Crunkhorn, S. (2014) Cancer: Predicting synthetic lethal interactions. *Nat Rev Drug Discov*, **13**(11): 812.
- Csardi, G. and Nepusz, T. (2006) The igraph software package for complex network research. *InterJournal*, **Complex Systems**: 1695.
- Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., *et al.* (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **486**(7403): 346–352.

- Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., and Shi, B. (2015) Breast cancer intrinsic subtype classification, clinical use and future trends. *Am J Cancer Res*, **5**(10): 2929–2943.
- Davierwala, A.P., Haynes, J., Li, Z., Brost, R.L., Robinson, M.D., Yu, L., Mnaimneh, S., Ding, H., Zhu, H., Chen, Y., *et al.* (2005) The synthetic genetic interaction spectrum of essential genes. *Nat Genet*, **37**(10): 1147–1152.
- De Leeuw, W.J., Berx, G., Vos, C.B., Peterse, J.L., Van de Vijver, M.J., Litvinov, S., Van Roy, F., Cornelisse, C.J., and Cleton-Jansen, A.M. (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. *J Pathol*, **183**(4): 404–11.
- Demir, E., Babur, O., Rodchenkov, I., Aksoy, B.A., Fukuda, K.I., Gross, B., Sumer, O.S., Bader, G.D., and Sander, C. (2013) Using biological pathway data with Paxtools. *PLoS Comput Biol*, **9**(9): e1003194.
- Deshpande, R., Asiedu, M.K., Klebig, M., Sutor, S., Kuzmin, E., Nelson, J., Piotrowski, J., Shin, S.H., Yoshida, M., Costanzo, M., *et al.* (2013) A comparative genomic approach for identifying synthetic lethal interactions in human cancer. *Cancer Res*, **73**(20): 6128–36.
- Dickson, D. (1999) Wellcome funds cancer database. *Nature*, **401**(6755): 729.
- Dienstmann, R. and Tabernero, J. (2011) *BRAF* as a target for cancer therapy. *Anti-cancer Agents Med Chem*, **11**(3): 285–95.
- Dijkstra, E.W. (1959) A note on two problems in connexion with graphs. *Numerische Mathematik*, **1**(1): 269–271.
- Dixon, S.J., Andrews, B.J., and Boone, C. (2009) Exploring the conservation of synthetic lethal genetic interaction networks. *Commun Integr Biol*, **2**(2): 78–81.
- Dixon, S.J., Fedyshyn, Y., Koh, J.L., Prasad, T.S., Chahwan, C., Chua, G., Toufighi, K., Baryshnikova, A., Hayles, J., Hoe, K.L., *et al.* (2008) Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes. *Proc Natl Acad Sci U S A*, **105**(43): 16653–8.
- Dorogovtsev, S.N. and Mendes, J.F. (2003) *Evolution of networks: From biological nets to the Internet and WWW*. Oxford University Press, USA.

- Dorsam, R.T. and Gutkind, J.S. (2007) G-protein-coupled receptors and cancer. *Nat Rev Cancer*, **7**(2): 79–94.
- Erdős, P. and Rényi, A. (1959) On random graphs I. *Publ Math Debrecen*, **6**: 290–297.
- Erdős, P. and Rényi, A. (1960) On the evolution of random graphs. In *Publ. Math. Inst. Hung. Acad. Sci*, volume 5, 17–61.
- Eroles, P., Bosch, A., Perez-Fidalgo, J.A., and Lluch, A. (2012) Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. *Cancer Treat Rev*, **38**(6): 698–707.
- Ezkurdia, I., Juan, D., Rodriguez, J.M., Frankish, A., Diekhans, M., Harrow, J., Vazquez, J., Valencia, A., and Tress, M.L. (2014) Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. *Human Molecular Genetics*, **23**(22): 5866.
- Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., *et al.* (2005) Targeting the dna repair defect in BRCA mutant cells as a therapeutic strategy. *Nature*, **434**(7035): 917–21.
- Fawcett, T. (2006) An introduction to ROC analysis. *Pattern Recognition Letters*, **27**(8): 861 – 874. {ROC} Analysis in Pattern Recognition.
- Fece de la Cruz, F., Gapp, B.V., and Nijman, S.M. (2015) Synthetic lethal vulnerabilities of cancer. *Annu Rev Pharmacol Toxicol*, **55**: 513–531.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., and Bray, F. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, **136**(5): E359–386.
- Fisher, R.A. (1919) Xv.the correlation between relatives on the supposition of mendelian inheritance. *Earth and Environmental Science Transactions of the Royal Society of Edinburgh*, **52**(02): 399–433.
- Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O’Connor, M.J., *et al.* (2009) Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med*, **361**(2): 123–34.

- Fong, P.C., Yap, T.A., Boss, D.S., Carden, C.P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., *et al.* (2010) Poly(adp)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. *J Clin Oncol*, **28**(15): 2512–9.
- Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., *et al.* (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. *Nucleic Acids Res*, **43**(Database issue): D805–811.
- Fraser, A. (2004) Towards full employment: using RNAi to find roles for the redundant. *Oncogene*, **23**(51): 8346–52.
- Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M.R. (2004) A census of human cancer genes. *Nat Rev Cancer*, **4**(3): 177–183.
- Futreal, P.A., Kasprzyk, A., Birney, E., Mullikin, J.C., Wooster, R., and Stratton, M.R. (2001) Cancer and genomics. *Nature*, **409**(6822): 850–852.
- Gao, B. and Roux, P.P. (2015) Translational control by oncogenic signaling pathways. *Biochimica et Biophysica Acta*, **1849**(7): 753–65.
- Gatza, M.L., Kung, H.N., Blackwell, K.L., Dewhirst, M.W., Marks, J.R., and Chi, J.T. (2011) Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes. *Breast Cancer Res*, **13**(3): R62.
- Gatza, M.L., Lucas, J.E., Barry, W.T., Kim, J.W., Wang, Q., Crawford, M.D., Datto, M.B., Kelley, M., Mathey-Prevot, B., Potti, A., *et al.* (2010) A pathway-based classification of human breast cancer. *Proc Natl Acad Sci USA*, **107**(15): 6994–6999.
- Gatza, M.L., Silva, G.O., Parker, J.S., Fan, C., and Perou, C.M. (2014) An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. *Nat Genet*, **46**(10): 1051–1059.
- Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., *et al.* (2004) Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol*, **5**(10): R80.

- Genz, A. and Bretz, F. (2009) Computation of multivariate normal and t probabilities. In *Lecture Notes in Statistics*, volume 195. Springer-Verlag, Heidelberg.
- Genz, A., Bretz, F., Miwa, T., Mi, X., Leisch, F., Scheipl, F., and Hothorn, T. (2016) *mvtnorm: Multivariate Normal and t Distributions*. R package version 1.0-5. URL.
- Gilbert, W. and Maxam, A. (1973) The nucleotide sequence of the lac operator. *Proceedings of the National Academy of Sciences*, **70**(12): 3581–3584.
- Git, A., Dvinge, H., Salmon-Divon, M., Osborne, M., Kutter, C., Hadfield, J., Bertone, P., and Caldas, C. (2010) Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. *RNA*, **16**(5): 991–1006.
- Globus (Globus) (2017) Research data management simplified. <https://www.globus.org/>. Accessed: 25/03/2017.
- Graziano, F., Humar, B., and Guilford, P. (2003) The role of the E-cadherin gene (*CDH1*) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. *Annals of Oncology*, **14**(12): 1705–1713.
- Güell, O., Sagus, F., and Serrano, M. (2014) Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis. *PLoS Comput Biol*, **10**(5): e1003637.
- Guilford, P. (1999) E-cadherin downregulation in cancer: fuel on the fire? *Molecular Medicine Today*, **5**(4): 172 – 177.
- Guilford, P., Hopkins, J., Harraway, J., McLeod, M., McLeod, N., Harawira, P., Taite, H., Scoular, R., Miller, A., and Reeve, A.E. (1998) E-cadherin germline mutations in familial gastric cancer. *Nature*, **392**(6674): 402–5.
- Guilford, P., Humar, B., and Blair, V. (2010) Hereditary diffuse gastric cancer: translation of *CDH1* germline mutations into clinical practice. *Gastric Cancer*, **13**(1): 1–10.
- Guilford, P.J., Hopkins, J.B., Grady, W.M., Markowitz, S.D., Willis, J., Lynch, H., Rajput, A., Wiesner, G.L., Lindor, N.M., Burgart, L.J., *et al.* (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. *Hum Mutat*, **14**(3): 249–55.

- Guo, J., Liu, H., and Zheng, J. (2016) SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets. *Nucleic Acids Res*, **44**(D1): D1011–1017.
- Hajian-Tilaki, K. (2013) Receiver Operating Characteristic (ROC) Curve Analysis for Medical Diagnostic Test Evaluation. *Caspian J Intern Med*, **4**(2): 627–635.
- Hall, M., Frank, E., Holmes, G., Pfahringer, B., Reutemann, P., and Witten, I.H. (2009) The weka data mining software: an update. *SIGKDD Explor Newsl*, **11**(1): 10–18.
- Hammerman, P.S., Lawrence, M.S., Voet, D., Jing, R., Cibulskis, K., Sivachenko, A., Stojanov, P., McKenna, A., Lander, E.S., Gabriel, S., *et al.* (2012) Comprehensive genomic characterization of squamous cell lung cancers. *Nature*, **489**(7417): 519–525.
- Han, J.D.J., Bertin, N., Hao, T., Goldberg, D.S., Berriz, G.F., Zhang, L.V., Dupuy, D., Walhout, A.J.M., Cusick, M.E., Roth, F.P., *et al.* (2004) Evidence for dynamically organized modularity in the yeast protein-protein interaction network. *Nature*, **430**(6995): 88–93.
- Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. *Cell*, **100**(1): 57–70.
- Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. *Cell*, **144**(5): 646–674.
- Hanna, S. (2003) Cancer incidence in new zealand (2003-2007). In D. Forman, D. Bray F Brewster, C. Gombe Mbalawa, B. Kohler, M. Piñeros, E. Steliarova-Foucher, R. Swaminathan, and J. Ferlay (editors), *Cancer Incidence in Five Continents*, volume X, 902–907. International Agency for Research on Cancer, Lyon, France. Electronic version <http://ci5.iarc.fr> Accessed 22/03/2017.
- Heiskanen, M., Bian, X., Swan, D., and Basu, A. (2014) caArray microarray database in the cancer biomedical informatics gridTM (caBIGTM). *Cancer Research*, **67**(9 Supplement): 3712–3712.
- Heiskanen, M.A. and Aittokallio, T. (2012) Mining high-throughput screens for cancer drug targets-lessons from yeast chemical-genomic profiling and synthetic lethality. *Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery*, **2**(3): 263–272.

- Hell, P. (1976) Graphs with given neighbourhoods i. problèmes combinatorics at theorie des graphes. *Proc Coil Int CNRS, Orsay*, **260**: 219–223.
- Herschkowitz, J.I., Simin, K., Weigman, V.J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K.E., Jones, L.P., Assefnia, S., Chandrasekharan, S., *et al.* (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. *Genome Biol*, **8**(5): R76.
- Hillenmeyer, M.E. (2008) The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science*, **320**: 362–365.
- Hoadley, K.A., Yau, C., Wolf, D.M., Cherniack, A.D., Tamborero, D., Ng, S., Leiserson, M.D., Niu, B., McLellan, M.D., Uzunangelov, V., *et al.* (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. *Cell*, **158**(4): 929–944.
- Hoehndorf, R., Hardy, N.W., Osumi-Sutherland, D., Tweedie, S., Schofield, P.N., and Gkoutos, G.V. (2013) Systematic analysis of experimental phenotype data reveals gene functions. *PLoS ONE*, **8**(4): e60847.
- Holm, S. (1979) A simple sequentially rejective multiple test procedure. *Scandinavian Journal of Statistics*, **6**(2): 65–70.
- Holme, P. and Kim, B.J. (2002) Growing scale-free networks with tunable clustering. *Physical Review E*, **65**(2): 026107.
- Hopkins, A.L. (2008) Network pharmacology: the next paradigm in drug discovery. *Nat Chem Biol*, **4**(11): 682–690.
- Hu, Z., Fan, C., Oh, D.S., Marron, J.S., He, X., Qaqish, B.F., Livasy, C., Carey, L.A., Reynolds, E., Dressler, L., *et al.* (2006) The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics*, **7**: 96.
- Huang, E., Cheng, S., Dressman, H., Pittman, J., Tsou, M., Horng, C., Bild, A., Iversen, E., Liao, M., Chen, C., *et al.* (2003) Gene expression predictors of breast cancer outcomes. *Lancet*, **361**: 1590–1596.
- Illumina, Inc (Illumina) (2017) Sequencing and array-based solutions for genetic research. <https://www.illumina.com/>. Accessed: 26/03/2017.

- International HapMap 3 Consortium (HapMap) (2003) The International HapMap Project. *Nature*, **426**(6968): 789–796.
- International Human Genome Sequencing Consortium (IHGSC) (2004) Finishing the euchromatic sequence of the human genome. *Nature*, **431**(7011): 931–945.
- Jerby-Arnon, L., Pfetzer, N., Waldman, Y., McGarry, L., James, D., Shanks, E., Seashore-Ludlow, B., Weinstock, A., Geiger, T., Clemons, P., *et al.* (2014) Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. *Cell*, **158**(5): 1199–1209.
- Joachims, T. (1999) Making large-scale support vector machine learning practical. In S. Bernhard, Ikonf, J.C.B. Christopher, and J.S. Alexander (editors), *Advances in kernel methods*, 169–184. MIT Press.
- Ju, Z., Liu, W., Roebuck, P.L., Siwak, D.R., Zhang, N., Lu, Y., Davies, M.A., Akbani, R., Weinstein, J.N., Mills, G.B., *et al.* (2015) Development of a robust classifier for quality control of reverse-phase protein arrays. *Bioinformatics*, **31**(6): 912.
- Kaelin, Jr, W. (2005) The concept of synthetic lethality in the context of anticancer therapy. *Nat Rev Cancer*, **5**(9): 689–98.
- Kaelin, Jr, W. (2009) Synthetic lethality: a framework for the development of wiser cancer therapeutics. *Genome Med*, **1**: 99.
- Kamada, T. and Kawai, S. (1989) An algorithm for drawing general undirected graphs. *Information Processing Letters*, **31**(1): 7–15.
- Kandoth, C., Schultz, N., Cherniack, A.D., Akbani, R., Liu, Y., Shen, H., Robertson, A.G., Pashtan, I., Shen, R., Benz, C.C., *et al.* (2013) Integrated genomic characterization of endometrial carcinoma. *Nature*, **497**(7447): 67–73.
- Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Arakawa, T., Hara, A., Fukunishi, Y., Konno, H., *et al.* (2001) Functional annotation of a full-length mouse cDNA collection. *Nature*, **409**(6821): 685–690.
- Kelley, R. and Ideker, T. (2005) Systematic interpretation of genetic interactions using protein networks. *Nat Biotech*, **23**(5): 561–566.

- Kelly, S., Chen, A., Guilford, P., and Black, M. (2017a) Synthetic lethal interaction prediction of target pathways in E-cadherin deficient breast cancers. Submitted to *BMC Genomics*.
- Kelly, S.T. (2013) *Statistical Predictions of Synthetic Lethal Interactions in Cancer*. Dissertation, University of Otago.
- Kelly, S.T., Single, A.B., Telford, B.J., Beetham, H.G., Godwin, T.D., Chen, A., Black, M.A., and Guilford, P.J. (2017b) Towards HDGC chemoprevention: vulnerabilities in E-cadherin-negative cells identified by genome-wide interrogation of isogenic cell lines and whole tumors. Submitted to *Cancer Prev Res*.
- Kozlov, K.N., Gursky, V.V., Kulakovskiy, I.V., and Samsonova, M.G. (2015) Sequence-based model of gap gene regulation network. *BMC Genomics*, **15**(Suppl 12): S6.
- Kranthi, S., Rao, S., and Manimaran, P. (2013) Identification of synthetic lethal pairs in biological systems through network information centrality. *Mol BioSyst*, **9**(8): 2163–2167.
- Lander, E.S. (2011) Initial impact of the sequencing of the human genome. *Nature*, **470**(7333): 187–197.
- Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., *et al.* (2001) Initial sequencing and analysis of the human genome. *Nature*, **409**(6822): 860–921.
- Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol*, **10**(3): R25.
- Latora, V. and Marchiori, M. (2001) Efficient behavior of small-world networks. *Phys Rev Lett*, **87**: 198701.
- Laufer, C., Fischer, B., Billmann, M., Huber, W., and Boutros, M. (2013) Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping. *Nat Methods*, **10**(5): 427–31.
- Law, C.W., Chen, Y., Shi, W., and Smyth, G.K. (2014) voom: precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol*, **15**(2): R29.

- Lawrence, M.S., Sougnez, C., Lichtenstein, L., Cibulskis, K., Lander, E., Gabriel, S.B., Getz, G., Ally, A., Balasundaram, M., Birol, I., *et al.* (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*, **517**(7536): 576–582.
- Le Meur, N. and Gentleman, R. (2008) Modeling synthetic lethality. *Genome Biol*, **9**(9): R135.
- Le Meur, N., Jiang, Z., Liu, T., Mar, J., and Gentleman, R.C. (2014) Slgi: Synthetic lethal genetic interaction. r package version 1.26.0.
- Lee, A.Y., Perreault, R., Harel, S., Boulier, E.L., Suderman, M., Hallett, M., and Jenna, S. (2010a) Searching for signaling balance through the identification of genetic interactors of the rab guanine-nucleotide dissociation inhibitor gdi-1. *PLoS ONE*, **5**(5): e10624.
- Lee, I., Lehner, B., Vavouri, T., Shin, J., Fraser, A.G., and Marcotte, E.M. (2010b) Predicting genetic modifier loci using functional gene networks. *Genome Research*, **20**(8): 1143–1153.
- Lee, I. and Marcotte, E.M. (2009) Effects of functional bias on supervised learning of a gene network model. *Methods Mol Biol*, **541**: 463–75.
- Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M., Sorger, P.K., MacBeath, G., and Yaffe, M.B. (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. *Cell*, **149**(4): 780–94.
- Lehner, B., Crombie, C., Tischler, J., Fortunato, A., and Fraser, A.G. (2006) Systematic mapping of genetic interactions in *caenorhabditis elegans* identifies common modifiers of diverse signaling pathways. *Nat Genet*, **38**(8): 896–903.
- Li, X.J., Mishra, S.K., Wu, M., Zhang, F., and Zheng, J. (2014) Syn-lethality: An integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies. *Biomed Res Int*, **2014**: 196034.
- Linehan, W.M., Spellman, P.T., Ricketts, C.J., Creighton, C.J., Fei, S.S., Davis, C., Wheeler, D.A., Murray, B.A., Schmidt, L., Vocke, C.D., *et al.* (2016) Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N Engl J Med*, **374**(2): 135–145.

- Lokody, I. (2014) Computational modelling: A computational crystal ball. *Nature Reviews Cancer*, **14**(10): 649–649.
- Lord, C.J., Tutt, A.N., and Ashworth, A. (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. *Annu Rev Med*, **66**: 455–470.
- Lu, X., Kensche, P.R., Huynen, M.A., and Notebaart, R.A. (2013) Genome evolution predicts genetic interactions in protein complexes and reveals cancer drug targets. *Nat Commun*, **4**: 2124.
- Lu, X., Megchelenbrink, W., Notebaart, R.A., and Huynen, M.A. (2015) Predicting human genetic interactions from cancer genome evolution. *PLoS One*, **10**(5): e0125795.
- Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K., Butler, J.S., Hinshaw, J.C., Garnier, P., Prestwich, G.D., Leonardson, A., *et al.* (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. *Cell*, **116**(1): 121–137.
- Luo, J., Solimini, N.L., and Elledge, S.J. (2009) Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction. *Cell*, **136**(5): 823–837.
- Machado, J., Olivera, C., Carvalh, R., Soares, P., Berx, G., Caldas, C., Sercuca, R., Carneiro, F., and Sorbrinho-Simoes, M. (2001) E-cadherin gene (*CDH1*) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. *Oncogene*, **20**: 1525–1528.
- Masciari, S., Larsson, N., Senz, J., Boyd, N., Kaurah, P., Kandel, M.J., Harris, L.N., Pinheiro, H.C., Troussard, A., Miron, P., *et al.* (2007) Germline E-cadherin mutations in familial lobular breast cancer. *J Med Genet*, **44**(11): 726–31.
- Mattison, J., van der Weyden, L., Hubbard, T., and Adams, D.J. (2009) Cancer gene discovery in mouse and man. *Biochim Biophys Acta*, **1796**(2): 140–161.
- Maxam, A.M. and Gilbert, W. (1977) A new method for sequencing DNA. *Proceedings of the National Academy of Science*, **74**(2): 560–564.
- McCourt, C.M., McArt, D.G., Mills, K., Catherwood, M.A., Maxwell, P., Waugh, D.J., Hamilton, P., O’Sullivan, J.M., and Salto-Tellez, M. (2013) Validation of next gen-

- eration sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis. *PLoS ONE*, **8**(7): e69604.
- McLachlan, J., George, A., and Banerjee, S. (2016) The current status of parp inhibitors in ovarian cancer. *Tumori*, **102**(5): 433–440.
- McLendon, R., Friedman, A., Bigner, D., Van Meir, E.G., Brat, D.J., Mastrogianakis, G.M., Olson, J.J., Mikkelsen, T., Lehman, N., Aldape, K., *et al.* (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*, **455**(7216): 1061–1068.
- Miles, D.W. (2001) Update on HER-2 as a target for cancer therapy: herceptin in the clinical setting. *Breast Cancer Res*, **3**(6): 380–384.
- Mortazavi, A., Williams, B.A., McCue, K., Schaeffer, L., and Wold, B. (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. *Nat Methods*, **5**(7): 621–628.
- Muzny, D.M., Bainbridge, M.N., Chang, K., Dinh, H.H., Drummond, J.A., Fowler, G., Kovar, C.L., Lewis, L.R., Morgan, M.B., Newsham, I.F., *et al.* (2012) Comprehensive molecular characterization of human colon and rectal cancer. *Nature*, **487**(7407): 330–337.
- Nagalla, S., Chou, J.W., Willingham, M.C., Ruiz, J., Vaughn, J.P., Dubey, P., Lash, T.L., Hamilton-Dutoit, S.J., Bergh, J., Sotiriou, C., *et al.* (2013) Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. *Genome Biol*, **14**(4): R34.
- Neeley, E.S., Kornblau, S.M., Coombes, K.R., and Baggerly, K.A. (2009) Variable slope normalization of reverse phase protein arrays. *Bioinformatics*, **25**(11): 1384.
- Novomestky, F. (2012) *matrixcalc: Collection of functions for matrix calculations*. R package version 1.0-3.
- Oliveira, C., Senz, J., Kaurah, P., Pinheiro, H., Sanges, R., Haegert, A., Corso, G., Schouten, J., Fitzgerald, R., Vogelsang, H., *et al.* (2009) Germline *CDH1* deletions in hereditary diffuse gastric cancer families. *Human Molecular Genetics*, **18**(9): 1545–1555.

- Oliveira, C., Seruca, R., Hoogerbrugge, N., Ligtenberg, M., and Carneiro, F. (2013) Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). *Eur J Hum Genet*, **21**(8).
- Pandey, G., Zhang, B., Chang, A.N., Myers, C.L., Zhu, J., Kumar, V., and Schadt, E.E. (2010) An integrative multi-network and multi-classifier approach to predict genetic interactions. *PLoS Comput Biol*, **6**(9).
- Parker, J., Mullins, M., Cheung, M., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., *et al.* (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. *Journal of Clinical Oncology*, **27**(8): 1160–1167.
- Peltonen, L. and McKusick, V.A. (2001) Genomics and medicine. Dissecting human disease in the postgenomic era. *Science*, **291**(5507): 1224–1229.
- Pereira, B., Chin, S.F., Rueda, O.M., Vollan, H.K., Provenzano, E., Bardwell, H.A., Pugh, M., Jones, L., Russell, R., Sammut, S.J., *et al.* (2016) Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. *Nat Commun*, **7**: 11908.
- Perou, C.M., Sørlie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., Rees, C.A., Pollack, J.R., Ross, D.T., Johnsen, H., Akslen, L.A., *et al.* (2000) Molecular portraits of human breast tumours. *Nature*, **406**(6797): 747–752.
- Polyak, K. and Weinberg, R.A. (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. *Nat Rev Cancer*, **9**(4): 265–73.
- Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012) Unresponsiveness of colon cancer to *BRAF*(v600e) inhibition through feedback activation of egfr. *Nature*, **483**(7387): 100–3.
- R Core Team (2016) *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria. R version 3.3.2.
- Ravnan, M.C. and Matalaka, M.S. (2012) Vemurafenib in patients with *BRAF* v600e mutation-positive advanced melanoma. *Clin Ther*, **34**(7): 1474–86.
- Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., and Smyth, G.K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*, **43**(7): e47.

- Robin, J.D., Ludlow, A.T., LaRanger, R., Wright, W.E., and Shay, J.W. (2016) Comparison of DNA Quantification Methods for Next Generation Sequencing. *Sci Rep*, **6**: 24067.
- Robinson, M.D. and Oshlack, A. (2010) A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol*, **11**(3): R25.
- Roguev, A., Bandyopadhyay, S., Zofall, M., Zhang, K., Fischer, T., Collins, S.R., Qu, H., Shales, M., Park, H.O., Hayles, J., *et al.* (2008) Conservation and rewiring of functional modules revealed by an epistasis map in fission yeast. *Science*, **322**(5900): 405–10.
- Rung, J. and Brazma, A. (2013) Reuse of public genome-wide gene expression data. *Nat Rev Genet*, **14**(2): 89–99.
- Rustici, G., Kolesnikov, N., Brandizi, M., Burdett, T., Dylag, M., Emam, I., Farne, A., Hastings, E., Ison, J., Keays, M., *et al.* (2013) ArrayExpress update—trends in database growth and links to data analysis tools. *Nucleic Acids Res*, **41**(Database issue): D987–990.
- Ryan, C., Lord, C., and Ashworth, A. (2014) Daisy: Picking synthetic lethals from cancer genomes. *Cancer Cell*, **26**(3): 306–308.
- Sander, J.D. and Joung, J.K. (2014) Crispr-cas systems for editing, regulating and targeting genomes. *Nat Biotechnol*, **32**(4): 347–55.
- Sanger, F. and Coulson, A. (1975) A rapid method for determining sequences in dna by primed synthesis with dna polymerase. *Journal of Molecular Biology*, **94**(3): 441 – 448.
- Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., *et al.* (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. *J Clin Oncol*, **20**(5): 1260–1268.
- Semb, H. and Christofori, G. (1998) The tumor-suppressor function of E-cadherin. *Am J Hum Genet*, **63**(6): 1588–93.
- Sing, T., Sander, O., Beerenwinkel, N., and Lengauer, T. (2005) Rocr: visualizing classifier performance in r. *Bioinformatics*, **21**(20): 7881.

- Slurm development team (Slurm) (2017) Slurm workload manager. <https://slurm.schedmd.com/>. Accessed: 25/03/2017.
- Sørlie, T., Perou, C.M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M.B., van de Rijn, M., Jeffrey, S.S., *et al.* (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc Natl Acad Sci USA*, **98**(19): 10869–10874.
- Stajich, J.E. and Lapp, H. (2006) Open source tools and toolkits for bioinformatics: significance, and where are we? *Brief Bioinformatics*, **7**(3): 287–296.
- Stratton, M.R., Campbell, P.J., and Futreal, P.A. (2009) The cancer genome. *Nature*, **458**(7239): 719–724.
- Ström, C. and Helleday, T. (2012) Strategies for the use of poly(adenosine diphosphate ribose) polymerase (parp) inhibitors in cancer therapy. *Biomolecules*, **2**(4): 635–649.
- Sun, C., Wang, L., Huang, S., Heynen, G.J.J.E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S.M., *et al.* (2014) Reversible and adaptive resistance to *BRAF*(v600e) inhibition in melanoma. *Nature*, **508**(7494): 118–122.
- Taylor, I.W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., Faria, D., Bull, S., Pawson, T., Morris, Q., and Wrana, J.L. (2009) Dynamic modularity in protein interaction networks predicts breast cancer outcome. *Nat Biotechnol*, **27**(2): 199–204.
- Telford, B.J., Chen, A., Beetham, H., Frick, J., Brew, T.P., Gould, C.M., Single, A., Godwin, T., Simpson, K.J., and Guilford, P. (2015) Synthetic lethal screens identify vulnerabilities in gpcr signalling and cytoskeletal organization in E-cadherin-deficient cells. *Mol Cancer Ther*, **14**(5): 1213–1223.
- The 1000 Genomes Project Consortium (1000 Genomes) (2010) A map of human genome variation from population-scale sequencing. *Nature*, **467**(7319): 1061–1073.
- The Cancer Genome Atlas Research Network (TCGA) (2012) Comprehensive molecular portraits of human breast tumours. *Nature*, **490**(7418): 61–70.
- The Cancer Genome Atlas Research Network (TCGA) (2017) The Cancer Genome Atlas Project. <https://cancergenome.nih.gov/>. Accessed: 26/03/2017.

- The Cancer Society of New Zealand (Cancer Society of NZ) (2017) What is cancer? <https://otago-southland.cancernz.org.nz/en/cancer-information/other-links/what-is-cancer-3/>. Accessed: 22/03/2017.
- The Catalogue Of Somatic Mutations In Cancer (COSMIC) (2016) Cosmic: The catalogue of somatic mutations in cancer. <http://cancer.sanger.ac.uk/cosmic>. Release 79 (23/08/2016), Accessed: 05/02/2017.
- The Comprehensive R Archive Network (CRAN) (2017) Cran. <https://cran.r-project.org/>. Accessed: 24/03/2017.
- The ENCODE Project Consortium (ENCODE) (2004) The ENCODE (ENCyclopedia Of DNA Elements) Project. *Science*, **306**(5696): 636–640.
- The National Cancer Institute (NCI) (2015) The genetics of cancer. <https://www.cancer.gov/about-cancer/causes-prevention/genetics>. Published: 22/04/2015, Accessed: 22/03/2017.
- The New Zealand eScience Infrastructure (NeSI) (2017) NeSI. <https://www.nesi.org.nz/>. Accessed: 25/03/2017.
- The Pharmaceutical Management Agency (PHARMAC) (2016) Approval of multi-product funding proposal with roche.
- Tierney, L., Rossini, A.J., Li, N., and Sevcikova, H. (2015) *snow: Simple Network of Workstations*. R package version 0.4-2.
- Tiong, K.L., Chang, K.C., Yeh, K.T., Liu, T.Y., Wu, J.H., Hsieh, P.H., Lin, S.H., Lai, W.Y., Hsu, Y.C., Chen, J.Y., *et al.* (2014) Csnk1e/ctnnb1 are synthetic lethal to tp53 in colorectal cancer and are markers for prognosis. *Neoplasia*, **16**(5): 441–50.
- Tischler, J., Lehner, B., and Fraser, A.G. (2008) Evolutionary plasticity of genetic interaction networks. *Nat Genet*, **40**(4): 390–391.
- Tomasetti, C. and Vogelstein, B. (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. *Science*, **347**(6217): 78–81.
- Tong, A.H., Evangelista, M., Parsons, A.B., Xu, H., Bader, G.D., Page, N., Robinson, M., Raghibizadeh, S., Hogue, C.W., Bussey, H., *et al.* (2001) Systematic genetic analysis with ordered arrays of yeast deletion mutants. *Science*, **294**(5550): 2364–8.

- Tong, A.H., Lesage, G., Bader, G.D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G.F., Brost, R.L., Chang, M., *et al.* (2004) Global mapping of the yeast genetic interaction network. *Science*, **303**(5659): 808–13.
- Travers, J. and Milgram, S. (1969) An experimental study of the small world problem. *Sociometry*, **32**(4): 425–443.
- Tsai, H.C., Li, H., Van Neste, L., Cai, Y., Robert, C., Rassool, F.V., Shin, J.J., Harbom, K.M., Beaty, R., Pappou, E., *et al.* (2012) Transient low doses of dna-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. *Cancer Cell*, **21**(3): 430–46.
- Tutt, A., Robson, M., Garber, J.E., Domchek, S.M., Audeh, M.W., Weitzel, J.N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R.K., *et al.* (2010) Oral poly(adenosine triphosphate) polymerase inhibitor olaparib in patients with *BRCA1* or *BRCA2* mutations and advanced breast cancer: a proof-of-concept trial. *Lancet*, **376**(9737): 235–44.
- van der Meer, R., Song, H.Y., Park, S.H., Abdulkadir, S.A., and Roh, M. (2014) RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition. *Clinical Cancer Research*, **20**(12): 3211–3221.
- van Steen, K. (2012) Travelling the world of genegene interactions. *Briefings in Bioinformatics*, **13**(1): 1–19.
- van Steen, M. (2010) *Graph Theory and Complex Networks: An Introduction*. Maarten van Steen, VU Amsterdam.
- Vapnik, V.N. (1995) *The nature of statistical learning theory*. Springer-Verlag New York, Inc.
- Vargas, J.J., Gusella, G., Najfeld, V., Klotman, M., and Cara, A. (2004) Novel integrase-defective lentiviral episomal vectors for gene transfer. *Hum Gene Ther*, **15**: 361–372.
- Vizeacoumar, F.J., Arnold, R., Vizeacoumar, F.S., Chandrashekhar, M., Buzina, A., Young, J.T., Kwan, J.H., Sayad, A., Mero, P., Lawo, S., *et al.* (2013) A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. *Mol Syst Biol*, **9**: 696.
- Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., and Kinzler, K.W. (2013) Cancer genome landscapes. *Science*, **339**(6127): 1546–1558.

- Vos, C.B., Cleton-Jansen, A.M., Berx, G., de Leeuw, W.J., ter Haar, N.T., van Roy, F., Cornelisse, C.J., Peterse, J.L., and van de Vijver, M.J. (1997) E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. *Br J Cancer*, **76**(9): 1131–3.
- Wang, K., Singh, D., Zeng, Z., Coleman, S.J., Huang, Y., Savich, G.L., He, X., Mieczkowski, P., Grimm, S.A., Perou, C.M., *et al.* (2010) MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. *Nucleic Acids Res*, **38**(18): e178.
- Wang, X. and Simon, R. (2013) Identification of potential synthetic lethal genes to p53 using a computational biology approach. *BMC Medical Genomics*, **6**(1): 30.
- Wappett, M. (2014) Bisep: Toolkit to identify candidate synthetic lethality. r package version 2.0.
- Wappett, M., Dulak, A., Yang, Z.R., Al-Watban, A., Bradford, J.R., and Dry, J.R. (2016) Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs. *BMC Genomics*, **17**: 65.
- Warnes, G.R., Bolker, B., Bonebakker, L., Gentleman, R., Liaw, W.H.A., Lumley, T., Maechler, M., Magnusson, A., Moeller, S., Schwartz, M., *et al.* (2015) *gplots: Various R Programming Tools for Plotting Data*. R package version 2.17.0.
- Watts, D.J. and Strogatz, S.H. (1998) Collective dynamics of 'small-world' networks. *Nature*, **393**(6684): 440–2.
- Weinstein, I.B. (2000) Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. *Carcinogenesis*, **21**(5): 857–864.
- Weinstein, J.N., Akbani, R., Broom, B.M., Wang, W., Verhaak, R.G., McConkey, D., Lerner, S., Morgan, M., Creighton, C.J., Smith, C., *et al.* (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*, **507**(7492): 315–322.
- Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J.M., Chang, K., *et al.* (2013) The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet*, **45**(10): 1113–1120.
- Wickham, H. and Chang, W. (2016) *devtools: Tools to Make Developing R Packages Easier*. R package version 1.12.0.

- Wickham, H., Danenberg, P., and Eugster, M. (2017) *roxygen2: In-Line Documentation for R*. R package version 6.0.1.
- Wong, S.L., Zhang, L.V., Tong, A.H.Y., Li, Z., Goldberg, D.S., King, O.D., Lesage, G., Vidal, M., Andrews, B., Bussey, H., *et al.* (2004) Combining biological networks to predict genetic interactions. *Proceedings of the National Academy of Sciences of the United States of America*, **101**(44): 15682–15687.
- World Health Organization (WHO) (2017) Fact sheet: Cancer. <http://www.who.int/mediacentre/factsheets/fs297/en/>. Updated February 2017, Accessed: 22/03/2017.
- Wu, M., Li, X., Zhang, F., Li, X., Kwoh, C.K., and Zheng, J. (2014) In silico prediction of synthetic lethality by meta-analysis of genetic interactions, functions, and pathways in yeast and human cancer. *Cancer Inform*, **13**(Suppl 3): 71–80.
- Yu, H. (2002) Rmpi: Parallel statistical computing in r. *R News*, **2**(2): 10–14.
- Zhang, F., Wu, M., Li, X.J., Li, X.L., Kwoh, C.K., and Zheng, J. (2015) Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates. *J Bioinform Comput Biol*, **13**(3): 1541002.
- Zhang, J., Baran, J., Cros, A., Guberman, J.M., Haider, S., Hsu, J., Liang, Y., Rivkin, E., Wang, J., Whitty, B., *et al.* (2011) International cancer genome consortium data portala one-stop shop for cancer genomics data. *Database: The Journal of Biological Databases and Curation*, **2011**: bar026.
- Zhong, W. and Sternberg, P.W. (2006) Genome-wide prediction of c. elegans genetic interactions. *Science*, **311**(5766): 1481–1484.
- Zweig, M.H. and Campbell, G. (1993) Receiver-operating characteristic (roc) plots: a fundamental evaluation tool in clinical medicine. *Clinical Chemistry*, **39**(4): 561–577.